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III Preface 
Preface 
 
 
The present PhD Thesis summarizes the scientific work performed in the research group of Prof. Dr. Ward 
from 2010-14 at the university of Basel. The main topic of the Ward group is the design of artificial 
metalloenzymes for asymmetric catalysis. These hybrid catatlysts result from the incorporation of a 
catalytically active transition metal complex within a host protein and thus combine properties of both 
traditional homogenous and biocatalysis. Moreover, the genetic tuneability of the protein scaffold allows 
to trigger the performance of an incorporated transition metal catalyst by modification of the second 
coordination sphere.  
The high affinity of the vitamin biotin towards the eucaryotic protein avidin (Avi) and its procaryotic 
counterpart streptavidin (Sav) offers an attractive strategy for the creation of artificial metalloenzymes.  
The conjugation of biotin with a catalytically active transition metal complex leads to an efficient 
incorporation of the latter within strept(avidin). This approach was applied extensively in the Ward group 
to obtain effective hybrid catalysts for a variety of reactions. The present work deals with the 
enantioselective reduction of prochiral imines to amines by artificial transfer hydrogenases (ATHase) which 
result from the incorporation of piano stool complexes of ruthenium, rhodium and iridium within Sav.   
The Thesis is divided into four chapters. The first chapter provides an introduction into the topic of artificial 
metalloenzymes and illustrates their potential in asymmetric catalysis. A review article summarizes the 
most recent achievments of this research field.  
The following two chapters present the research performed in context of several projects which resulted in 
four scientific publications. A brief introduction into the respective topic is given in each chapter. The 
author's contribution to each publication is highlighted in a preamble. An appendix at the end of each 
chapter presents additional results which did not appear in the corresponding publications. 
 
IV Preface 
Chapter two describes the genetic optimization of the ATHase and gives mechanistic insights in its 
operating mode. Chapter three focuses on attempts to implement transition metal catalysis in vivo. This 
would open fascinating perspectives to enable directed evolution of artificial metalloenzymes. Detailed 
procedures of experiments described in the appendices are given in chapter four. 
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Chapter 1: Introduction 
 
 
 
1.1 Background of the Thesis 
 
1.1.1 Chirality 
The term "chirality" describes the property of a molecule possessing no improper rotation axis to appear in 
two distinct forms which are the mirror image of each other. The two mirror images of a chiral molecule 
are called "enantiomers" and are not superimposable. Therefore, they behave like a right and a left hand 
(chirality = handedness, derived from the Greek term "cheir" = hand). The most common type of chirality 
relies on a tetrahedral central atom (stereogenic center) bearing four different substituents ("central 
chirality"). Compounds bearing multiple stereogenic centers are called "diastereoisomers" and comprise 
isomers which differ with respect to their three-dimensional arrangement but do not behave like mirror-
images. 
In contrast to diastereoisomers, enantiomers exhibit the same physical properties (e.g. boiling point, 
solubility) apart from the fact that their interaction with linearly polarized light is different in such a way 
that its polarized plane is rotated by the same angle but in opposite directions. A macroscopic rotation of 
the polarization plane results if a single enantiomer is present or if one enantiomer is enriched compared to 
the other one; a phenomenon which is called "optical activity". A 1:1 mixture of two enantiomers is called 
"racemate" and shows no optical activity as the effect of both enantiomers on the rotation of the polarization 
plane cancels out. By definition, substances that rotate polarized light to the right are indicated with the 
prefix "(+)" whereas compounds rotating light to the left are indicated with the prefix "(–)". The current 
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IUPAC nomenclature for enantiomers is based on the Cahn-Ingold-Prelog rules, using "(S)" for sinister 
(left) and "(R)" for rectus (right).1 It should be noted that this nomenclature is not related to optical rotation.  
Chirality is a prevalent feature in nature and many natural compounds such as amino acids, carbohydrates 
or nucleotides as well as their respective biopolymers (proteins, oligosaccharids, DNA/RNA) exist almost 
exclusively as a single enantiomer. As a consequence, the two enantiomers of a particular small molecule 
(e.g. a drug) will interact in a different way with such a biopolymer (e.g. a particular enzyme which may 
cause a certain disease). The two enantiomers of a drug can thus have dramatically different biological 
effects. A very prominent and often-quoted example in this context is Thalidomide, the active component 
in the pharmaceutical Contergan which was sold as a racemate in the late 50's and early 60's of the last 
century to treat ahypnosis (Figure 1.2). It turned out that only the (+)-(R)-enantiomer exhibited the desired 
sedative effect whereas the (–)-(S)-enantiomer was teratogenic and caused birth defects when administered 
to pregnant women.2 It should be noted that this problem would not be solved upon administering (+)-(R)-
Contergan is it readily racemises under physiological conditions. Another prominent example in this 
context is the natural product carvone: the (–)-(R)-enantiomer smells like spearmint, the (+)-(S)-counterpart 
on the other hand smells like caraway.3 These two examples convincingly demonstrate the different effects 
that enantiomers display in the presence of the enantiopure macromolecules of Life.  
 
 
 
Figure 1.1. Selected examples of the effect of chirality on the properties of enantiopure compounds. The dashed lines 
indicate mirror planes. 
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Approximately 50 % of all pharmaceutical compounds available on the market nowadays are chiral. 
Although many drugs are still sold as a racemate, there is a clear trend towards marketing enantiopure drugs 
as the costs of studies which elucidate the toxicological and pharmacokinetic profile of the unwanted 
enantiomer are usually higher than the development of an enantioselective synthetic procedure.4 Such a 
“chiral switch” strategy allows to extend the patent life of a drug without having to go through all clinical 
trials.  
  
    
 
1.1.2 Asymmetric Catalysis 
1.1.2.1 General Principles and Definitions 
Different approaches have been developed to introduce stereocenters into molecules for the production of 
drugs and fine chemicals. In some cases, chiral elements derived from enantiopure natural products such as 
carbohydrates and amino acids can be incorporated at a certain stage of a synthetic procedure. If not 
provided by the "chiral pool", enantiopure stereocenters can be generated by resolution, the use of chiral 
auxiliaries or asymmetric catalysis.5 The latter is the most efficient method in this context as a small amount 
of a chiral catalyst may produce large quantities of an enantio-enriched product whereas resolution limits 
the maximal theoretical yield to 50% and the application of chiral auxiliaries requires additional steps to 
tether and cleave the auxiliary.  
Two distinct classes of homogenous catalysts are predominantly used in asymmetric synthesis, namely 
chiral transition metal complexes and enzymes. Despite their structural and functional differences, both 
types of catalysts rely on the same general mechanisms of stereoselection. The interaction of the 
enantiopure catalyst with either one or the other prochiral face of the substrate gives rise to the formation 
of two diastereomeric transition states which possess different energies. The energy difference G‡ of the 
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two transition states is directly related to the enantiomeric excess (ee) of an asymmetric catalytic 
transformation.6 
ee (%) =
 e–(∆∆G
‡/RT) – 1
 e–(∆∆G
‡/RT) + 1
= 
[major enantiomer] – [minor enantiomer]
[major enantiomer] + [minor enantiomer]
  
The number of moles of product a catalyst can produce before being deactivated is called "turnover number" 
(TON = molar ratio of product and catalyst) and is related to the life-time and activity of a catalyst. The 
latter property is refered to the "turnover frequency" (TOF) and is defined as the turnover number per time 
unit.      
 
1.1.2.2 Homogenous Transition Metal Catalysis 
The use of transition metal complexes in catalysis relies on the versatile reactivity and the tuneability of 
these compounds. Transition metals can switch between different oxidation states and therefore are able to 
abstract and eliminate certain fragments of molecules, thus enabling processes which are involved in 
catalytic cycles such as oxidative addition or reductive elimination. Moreover, by choice of the appropriate 
ligand the electron density and the steric environment of the metal can be influenced. This feature not only 
allows to fine-tune the reactivity and selectivity (e.g. chemo- and regioselectivity) of the catalyst, but also 
affords an opportunity to perform asymmetric catalysis using transition metals in combination with 
enantiopure ligands which provide the asymmetry. Frequently, both enantiomers of a chiral ligand can be 
prepared, e.g. by fractional recrystallisation of a diastereomeric salt,7 giving access to both product 
enantiomers with the same asymmetric transformation.  
The Nobel Prize 2001 was awarded to W.S. Knowles8 and R. Noyori9 who used chiral phosphine ligands 
for the asymmetric hydrogenation of functionalized alkenes and to B. Sharpless10 who applied enentiopure 
ligands derived from natural products for the asymmetric epoxidation and dihydroxylation of olefins, 
respectively. These pioneering achievements revealed the potential of homogenous catalysts in asymmetric 
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synthesis and gave rise to the development of asymmetric variants of many other transformations such as 
Diels-Alder reactions, Michael additions, Aldol reactions, etc.11 In parallel, the scope of enantiopure ligands 
was continuously expanded. Among these, certain scaffolds afford catalysts which provide high 
enantioselectivities in a wide range of asymmetric transformations and therefore are termed "privileged 
chiral ligands" (Figure 1.2).12  
 
 
Figure 1.2. Privileged ligands and reactions catalyzed by corresponding transition metal complexes.12 
 
 
1.1.2.3 Biocatalysis 
Although enzymes underlie the same general principles of (asymmetric) catalysis as homogenous catalysts, 
they differ from the latter due to some unique features which primarily are the result of natural selection 
during the evolution of living organisms. Outstanding properties of biocatalysts include their high catalytic 
activity at ambient conditions, their substrate specificity and their high selectivity with respect to chemo-, 
regio- and enantioselectivity.13 The rates of enzyme-catalyzed reactions can be increased by a factor of up  
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to 1017 compared to the corresponding non-catalyzed reactions and enantioselectivities of 99 % ee are 
achieved routinely in case of asymmetric transformations.14 This efficiency still outperforms by far the 
catalytic potential of the most chemical catalysts. Two specific features which contribute to the high 
effectiveness of enzymes differ significantly from homogenous catalysis and therefore are briefly 
summarized in the following.  
First, enzymes are able to stabilize the transition state of a reaction.15 This generally accepted basic 
mechanism of enzymatic catalysis was first formulated by Haldane16 and expanded by Pauling17 and 
Wolfenden.18 According to their concept, enzymes lower the Gibbs energy G‡ of a reaction by binding the 
corresponding transition state with higher affinity than the ground state of the substrate(s). Thereby, the 
fraction of the reactant in the transition state is raised. The resulting increase of the effective concentration 
of this intermediate is proportional to the reaction rate and therefore results in an acceleration of the reaction. 
This model is supported by the fact that some enzymes are strongly inhibited by transition state analogues19 
and is the basic concept of catalytic antibodies.20  
Different catalytic features provided by enzymes directly contribute to the stabilization of the transition 
state (figure 1.3), including general-acid/base catalysis (proton transfer mediated by acidic and basic amino 
acid residues), electrostatic catalysis (stabilization of charges by complementary charged amino acid 
residues or hydrogen bonds) and electrophilic catalysis (stabilization of negative charges by metal ions).21  
Second, enzymes may serve as an "entropic trap".22 Upon binding in the active site, substrates and/or 
reactive amino acid residues are aligned in a relative position to each other which is favorable to promote 
a reaction. As the translational and rotational freedom of the reactants is restricted when bound to the 
enzyme, the subsequent formation of the transition state might not be expected to require as much entropy 
loss as for the same reaction proceeding spontaneously in dilute solution.23 The consequence of substrate-
binding within the enzyme can be viewed as a transformation of an intermolecular reaction into an 
entropically more favored and therefore faster intramolecular reaction.24 Since the reacting groups are in 
close proximity if they are part of the same molecule or located in the active site of an enzyme, their 
effective concentration is increased. The rate acceleration in a monomolecular enzymatic or intramolecular 
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reaction compared to a bimolecular reaction may be expressed as an "effective molarity"  of one reacting 
group or molecule relative to the other (EM = ratio between the first-order rate constant of an intramolecular 
reaction and the second-order rate constant of the corresponding intermolecular reaction).25 However, the 
degree of contribution of these entropic effects to enzyme catalysis is still under discussion.26 
 
 
Figure 1.3. The catalytic cycle of serine proteases illustrates the different mechanisms of enzymatic catalysis.21 The 
active site consists of a "catalytic triad" formed by the three conserved residues Asp-102, His-57 and Ser 195. The 
deprotonated hydroxyl group of the latter (acid-base catalysis) attacs the carbonyl group of the amide bond whereupon 
an anionic tetraedral intermediate is formed (covalent catalysis) which is stabilized through hydrogen bondings 
provided by the "oxyanion hole" consisting of the backbone NH-groups of Gly-193 and Ser-195 (electrostatic 
catalysis). The RNH-group is activated as a leaving group after protonation by His-57 (acid-base catalysis). The 
resulting acylenzyme is hydrolysed by a water molecule activated as a nucleophile after deprotonation by His-57 
(acid-base catalysis), yielding the second tetrahedral intermediate (electrostatic catalysis) and regenerating the 
enzyme.      
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The advent of recombinant DNA technology in the 1970s and the consecutive improvement of high-
performance expression systems significantly increased the availability of biocatalysts. New protein 
engineering techniques such as rational design and directed evolution protocols nowadays allow to improve 
important features of enzymes with respect to organic chemistry (see below).27 Thanks to these 
achievements, biocatalysis has become a versatile tool in the synthesis of fine chemicals and is used to 
catalyze a variety of stereoselective reactions such as hydrolysis, oxygenations, reductions, 
transaminations, Aldol reactions, Diels-Alder reactions etc.28 Moreover, enzymes find increasing 
applications in industrial processess were they complement homogenous catalysts.29 
 
 
1.1.2.4 Complementary of Homogenous and Biocatalysis 
Despite their great catalytic potential, enzymes suffer from some major drawbacks with respect to organic 
synthesis. They often exhibit a narrow substrate scope and have only limited stability under conditions 
commonly applied in organic reactions such as the use of organic solvents, high temperatures and extreme 
pH-values. Additionally, only one product enantiomer is available with a given biocatalyst which applies 
to a lesser extent in case of homogenous transition metal catalysts (see section 1.1.2.2). Moreover, the latter 
often operate well at high temperatures and pressures (e.g. in hydrogenations).   
With regard to the individual advantages and drawbacks of homogenous catalysts and enzymes both 
catalytic systems can be viewed as complementary. This statement has been illustrated recently in context 
of the synthesis of Sitagliptin 1 (figure 1.4). The compound is the active ingredient in Januvia, a leading 
drug for the treatment of type 2 diabetes.30 Key step of the synthesis is the stereoselective introduction of 
the primary amine in the -amino acid moiety of 1. In the initial process chemistry route, this was 
implemented by asymmetric hydrogenation of the -ketoester 2 using < 0.1 mol% (S-BINAP)RuCl2 in 
presence of HBr.31 After ester hydrolysis the resulting -hydroxyester 3 was isolated with 83 % yield and 
94% ee. Although this process enabled the production of large amounts (> 100 kg) of the target compound 
  
9 Chapter 1: Introduction  
for early clinical studies, this first generation process of Sitagliptin manufacture was discarded due to the 
generation of large amounts of waste in the following steps which converts the hydroxyl into the protected 
amine group. A collaboration between Merck and Solvias led to a second generation process which avoids 
the introduction of protecting groups and produced less waste. A screening of different metal precursors 
(Ru, Rh, Ir) and chiral ligands led to the identification of [Rh(COD)Cl]2 (0.15 mol%) which in combination 
with t-BuJOSIPHOS (0.155 mol%) allowed tohydrogenate the unprotected -aminoamide 4 in 98%  yield 
95% ee.32 Subsequently, a reductive amination procedure was developped which converted 5 in presence 
of amonium salicylate, hydrogen and [(R-DM-SEGPHOS)Ru(OAc)2] directly to Sitagliptin in 91% yield 
and 99.5% ee, thus further improving the enantioselectivity and circumventing the prior formation of the 
enamide.33 Since the asymmetric hydrogenation requires a high-pressure equipment and an additional 
purification process is necessary to remove the transition metal from the product, there was still room for 
improvement with regard to a large-scale production of the drug.  
Another collaboration between Merck and Codexis provided an enzymatic route to Sitagliptin ("third 
generation process"). This approach relies on the in silico design and directed evolution of a (R)-selective 
transaminase ATA-117, a homolog of an enzyme of from Arthrobacter sp.34 The active site of 
transaminases consists of two binding sites of which one accommodate the large substituent and the other 
one the small substituent of the ketone substrate whereas the latter is usually not larger as a methyl-group. 
To expand the substrate scope of the transaminase to the Sitagliptin precursor 5 a "substrate walking" 
approach was applied. In a first step the large binding pocket was engineered towards accommodation of a 
truncated version of 5 bearing a methyl group instead of the trifluorophenyl moiety. In a second step, the 
activity of most efficient transaminase towards 5 resulting from the first step was further evolved under 
consideration of the reaction conditions applied in the chemical plant such as the presence of DMSO, 
elevated temperatures, high substrate concentrations and high concentrations of the nitrogen donor 
isopropylamine. After eleven rounds of directed evolution, the original biocatalyst had been modified at 27 
positions, including substitutions in the active site and the interface of the enzyme dimer which were linked 
with the higher stability of the catalyst under the reaction conditions. The related enzymatic process for the 
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production of Sitagliptin operates at 200 gl-1 5 with a substrate to catalyst ratio of 2600 in presence of 50 % 
DMSO at 40 °C, yielding the product with 92% yield and >99.95% ee. 
This impressive case study of the Sitagliptin manufacture demonstrates not only the complementary of   
homogenous and biocatalysis, but also illustrates the progress which has been achieved in the industrial 
application of biocatalysts. Applying a combination of computational enzyme design and laboratory 
evolution enabled the creation of an enzyme with a high activity and selectivity towards a non-native 
substrate and increased stability towards elevated temperatures as well as organic solvents.   
 
 
Figure 1.4. Enantioslective transformations in the manufacture of Sitagliptin.  
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1.1.3 Artificial Metalloenzymes 
 
1.1.3.1 General Concepts and Design of Artificial Metalloenzymes 
Almost half of all enzymes found in nature require metal ions for their catalytic function. So far, a great 
diversity of both main group and transition metals have been identified as a component in metalloenzymes, 
including Na, K, Ca, Mg, Fe, Mn, Zn, Co, Ni, Cu, V, Mo, W and Cd.35 The respective ions are either 
coordinated by functional groups of amino acid side chains (e.g. Zn2+ in carbonic anhydrase) or are part of 
a cofactor (e.g. Fe2+ in heme of cytochromes). Metalloenzymes mediate various catalytic mechanisms such 
as electrophilic catalysis (e.g. alcohol dehydrogenase),36 hydrolysis (e.g. carbonic anhydrase),37 oxygen 
transport (e.g. hemoglobin),38 hydroxylation (e.g. cytochrome P450),39 methyl transfer (e.g. cobalamin-
dependent methionine synthase)40 and electron transport (e.g. cytochromes).41 The fact that metalloenzymes 
are involved in fundamental biological processes including nitrogen-fixation as well as photosynthesis 
underlines their importance and illustrates their remarkable catalytic features.  
Artificial metalloenzymes result from the incorporation of a catalytically active transition metal complex 
within a biomolecular scaffold (i.e. a protein or DNA/RNA).42 The primary goal of this approach is to 
combine the reaction scope offered by traditional homogenous catalysts with the advantageous properties 
of biocatalysts, in particular the high activity at ambient conditions and the high selectivity (see previous 
section). These features are almost exclusively controlled by the ligand forming the first coordination sphere 
in the case of transition metal complexes. In contrast, the selectivity and activity of enzymes relies 
predominantly on the second coordination sphere provided by hydrophobic interactions and hydrogen 
bonds which are responsible for the chiral discrimination, the stabilization of the transition state of the 
reaction and/or the activation of the substrate by secondary interactions. In particular the last two tasks are 
more difficult to achieve with low molecular-weight ligands employed in homogenous catalysis. Thus, the 
performance of a homogenous catalyst may be improved with respect to activity and selectivity when 
incorporated within a protein scaffold. For instance, Zhang et al. were able to improve the chemoselectivity 
of a Mn-salen complex for the oxidation of thioanisole upon incorporation into apo-myoglobin.43 Whereas 
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the free metal complex produced significant amounts of the sulfone product, over oxidation was completely 
suppressed in case of the corresponding hybrid catalyst, yielding exclusively the sulfide.  
On the other hand, since certain activities provided by homogenous catalysts are absent in nature, artificial 
metalloenzymes may increase the catalytic repertoire for applications in biocatalysis and synthetic biology. 
To date, many non-natural reactions including olefin metathesis could be implemented in various 
biomolecular scaffolds.44   
Three main strategies for the creation of artificial metalloenzmes are usually applied (Figure 1.5).45 In the 
dative anchoring strategy, a metal ion is coordinated by specific amino acid residues (e.g. histidine, 
aspartate) which already are present in the protein or are engineered by means of site-directed mutation. In 
some cases, a native metal present in the protein is exchanged by an abiotic one. An example of the latter 
procedure was reported by Kazlauskas who substituted the zinc ion in carbonic anhydrase by rhodium to 
afford a hydroformylase or hydrogenase.46  
The covalent anchoring strategy relies on the covalent attachment of a catalytic moiety on a reactive amino 
acid residue which can be modified selectively. In this context, artificial metalloenzymes based on 
modification of cysteine,47 serine48 and lysine49 have been reported.  
Supramolecular anchoring takes advantage of a strong, specific interaction between a protein and a 
particular ligand (e.g. a substrate or inhibitor). Derivatization of the ligand with a metal complex results in 
the incorporation of the abiotic cofactor within the host. This strategy was applied extensively in the Ward 
group using the biotin-(strept)avidin technology (see below). More examples of artificial metalloenzymes 
and their respective anchoring strategies are provided in section 1.1.4.  
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Figure 1.5. Selected examples of strategies to create artificial metalloenzymes. a) dative anchoring46 b) covalent 
anchoring47 c) supramolecular anchoring.  
 
1.1.3.2 Artificial Metalloenzymes Based on the (Strept)avidin-Biotin Technology 
Avidin (Avi, from egg-white) and streptavidin (Sav, from Streptomycetes avidinii) are particularly well 
known for their high affinity towards the vitamin biotin (Ka = ~1015 M-1 for Avi and ~1013 - 1014 M-1 for 
Sav, respectively).50 The two related proteins (32 % sequence homology) have a similar homotetrameric 
structure which can be described as a dimer of dimers with D2-symmetry.51 Each monomer consists of an 
eight-stranded -barrel and binds one biotin molecule. The quaternary structure is stabilized predominately 
by a network of van der Waals interactions and hydrogen bonds between each individual monomer.52 In 
contrast to streptavidin (Mr = 65700 D) which is devoid of sulfur-containing amino acids, avidin (Mr = 
62400 D) contains two cysteines forming a disulfide-bridge and two methionine residues. In addition, 
avidin is glycosylated at Asn-17. 
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Fig. 1.6. X-ray crystal structure of the Streptavidin monomer (PDB-code: 1STP). Biotin and interacting amino acid 
residues are displayed as sticks (carbon: grey, oxygen: red, nitrogen: blue). Left: hydrophilic interactions. Right: 
hydrophobic interactions. Trp-120 is not shown.  
 
 
 
In both proteins, the biotin binding sites are located at the entrance of the -barrel. The network of 
hydrophilic interactions involved in biotin-binding is similar in both cases. As illustrated in Figure 1.6 for 
streptavidin, hydrogen bonds are formed with the carbonyl oxygen (Asn-23, Ser-27, Tyr-43) as well as the 
NH-groups (Ser-45, Asp-128) of the ureido moiety, the sulfur of the thiolane moiety (Thr-90) and the 
carboxyl group of the valeric acid chain (Asn-49, Ser-88).53 The five hydrogen bonds of the ureido moiety 
act cooperatively, leading to stabilization that is larger than the sum of the individual hydrogen-bonding 
energies and therefore may contribute to the high affinity towards biotin.54  In addition, the Trp-residues 
79, 92 and 108 from one monomer as well as Trp-120 from the adjacent monomer are responsible for 
hydrophobic interactions between streptavidin and biotin. Energetically, the high affinity can be explained 
with the large activation barrier for dissociation (G‡Sav = 102 kJ/mol) which results in a high activation 
enthalpy (H‡Sav = 134 kJ/mol) and a favorable activation entropy (TS‡Sav = 32 kJ/mol).55   
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In the apoprotein of both avidin and streptavidin, the loop connecting the strands 3 and 4 of the -barrel 
changes its conformation upon biotin-binding and thereby "closes" the binding site such that the ligand is 
buried almost completely. Both cooperative and non-cooperative binding of biotin to the (strept)avidin 
tetramer have been reported.56            
Avidin and streptavidin are extremely stable over a wide pH range and with respect to high temperatures, 
the presence of denaturating agents as well as organic solvents.57 For instance, up to 20 minutes are required 
to dissociate streptavidin into monomers at 100 °C in 0.2 % sodium dodecyl sulphate (SDS).58 To denature 
the monomers and release bound biotin even more drastic conditions have to be applied (e.g. 6 M 
guandidinium hydrochloride, pH 1.5). Binding of biotin significantly increases the thermostability of both 
proteins as reflected by the increased melting temperatures which in case of streptavidin is increased from 
Tm = 75 °C for the apoprotein to Tm = 112 °C for the fully biotin-saturated complex.59  
The high affinity towards biotin and the stability of (strept)avidin have led to many applications in research. 
These are commonly summarized under the concept of "biotin-(strept)avidin technology".60 The 
derivatization at the carboxylic acid moiety of the valeric chain of biotin does not significantly decrease the 
affinity of the resulting conjugate towards (strept)avidin and therefore allows to label the host protein with 
a target molecule of interest. The corresponding probe (e.g. a fluorescent dye) is usually linked to the biotin 
anchor via an appropriate spacer (e.g. a polyethylene glycol chain) and thus does not interact with the Avi 
or Sav. This technique is well established nowadays and has been applied to affinity chromatography, 
diagnostics, immunoassays, drug targeting, etc.61 
In 1978, Whitesides and coworkers reported for the first time an artificial metalloenzyme on the basis of 
the biotin-(strept)avidin technology.62 The incorporation of an achiral biotinylated Rh(I)-bisphosphine 
complex into avidin resulted in an artificial hydrogenase which catalyzed the enantioselective reduction of 
N-acetamidoacrylate with 41 % ee in favor of the (S)-enantiomer. Inspired by this visionary work, the Ward-
group adapted and extended this supramolecular anchoring strategy relying on the strength of the 
noncovalent (strept)avidin-biotin interaction for the creation of artificial metalloenzymes. Initial 
experiments using avidin in the combination with two distinct Rh(I)-complexes Biot-1 and Biot-2 (Figure 
 
16 Chapter 1: Introduction 
1.7) yielded only modest enantioselectivities in the hydrogenation of N-acetamidoacrylate.63 The 
asymmetric hydrogenation was significantly improved when streptavidin was used as the host protein 
instead of avidin, achieving up to 96 % ee for the opposite (R)-enantiomer. It was concluded that the 
different topography of the binding pocket is responsible for the improved asymmetric induction in case of 
streptavidin.64 The diversity of the hybrid catalysts was further increased by a chemogenetic optimization 
approach. For this purpose, the linker between the two phosphine ligands and the biotin anchor was 
modified whereby either alkylaminoacids of different chain lengths or arylaminoacids with a different 
substitution pattern were introduced.65 Combination of the corresponding Rh(I) complexes with selected 
streptavidin mutants revealed that amino acid substitutions of the second coordination sphere of the biotin 
binding (e.g. V47G) site and those which lie in close proximity to the metal center (e.g. S112G) provide 
the highest variability with respect to the absolute configuration and enantiomeric excess of the product. 
Based on the identification of S112 as a crucial position in streptavidin with regard to the performance of 
the hybrid catalysts, saturation mutagenesis at this position led to the identification of mutants with 
increased enantioselectivity in the hydrogenation of -acetamidocinnamic acid. The introduction of chiral 
amino acid spacers (proline or phenylalanine) between biotin and the aminodiphosphine moiety of Biot-1 
combined with saturation mutagenesis at position S112 afforded a second generation of artificial 
hydrogenases with improved organic solvent tolerance, reaction rates and selectivities (≥ 95 % ee for both 
enantiomers).66 Furthermore, it could be shown that the hybrid catalysts display Michaelis-Menten behavior 
with increased affinities (smaller KM-values) and rates (higher kcat-values) compared to the Rh-complexes 
in absence of streptavidin.  
This "designed evolution" approach was expanded for the optimization of artificial metalloenzymes based 
on the biotin-(strept)avidin technology for olefin metathesis,44 asymmetric allylic alkylation,67 C-H 
activation68 and transfer hydrogenation of ketones.69 Furthermore, it has been shown that (strept)avidin is 
also a suitable host for non-biotinylated artificial metal cofactors such as OsO4 and [VO(H2O)5]2+ which are 
also believed to bind in the biotin binding pocket via complexation to specific amino acid residues or second 
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coordination sphere interactions, respectively. The corresponding artificial metalloenzymes proved to be 
effective catalysts for the enantioselective sulfoxidation70 and dihydroxylation.71 
 
 
 
Fig. 1.7. Design of artificial hydrogenases based on the Biotin-(Strept)avidin technology. a) Reaction scheme showing 
the reduction of N-acetamidoacrylate by the artificial hydrogenase. b) Artificial metal cofactor reported by Whitesides. 
c) Design strategy to generate chemical diversity of the arificial metal cofactor reported by Ward et al.  
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1.1.4 Recent Achievements in the Design and Engineering of Artificial Metalloenzymes 
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1.2 Goal of the Thesis 
 
 
Artificial transfer hydrogenanses (ATHase) result from the incorporation of biotinylated piano stool metal 
complexes [(ηn-arene)M(biot-p-L)Cl] (M = Ru, Rh, Ir) into strept(avidin). These hybrid catalysts were 
succesfully applied for the asymmetric transfer hydrogenation of prochiral ketones in the Ward group in 
the last decade (see below). In this context, the aims of the present Thesis are: 
 
i) expanding the substrate scope of artificial transfer hydrogenases to the asymmetric reduction of prochiral 
imines 
ii) optimization of the artificial imine reductase with respect to the amino acid composition of the active 
site and the reaction conditions  
iii) performing the Michaelis-Menten kinetics of ATHases catalysts to gain information about the 
mechanism of the hybrid catalysts 
iv) enable catalysis with the ATHases in cellular environments (cell free extracts and cell lysates) by 
identification of reagents which neutralize the dentrimetal effect of glutathione (GSH) on precious metal 
catalysts 
v) illustrating the compatibility of homogenous and biocatalysis by performing reaction cascades with 
ATHases in combination with several natural enzymes   
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Chapter 2: Design and Genetic Optimization of an Artificial Transfer 
Hydrogenase (ATHase) 
 
 
2.1 Introduction 
 
 
2.1.1 Homogenous Asymmetric Transfer Hydrogenation 
 
2.1.1.1 Asymmetric Transfer Hydrogenation of Ketones 
Asymmetric transfer hydrogenation can be viewed as a transition metal catalyzed asymmetric variant of the 
Meerwein-Ponndorf-Verley reduction in which ketones and aldehydes are reduced to alcohols using 
isopropanol as a reducing agent and aluminium alkoxides as catalysts.1 Therefore, this reaction provides a 
versatile alternative to classic hydrogenation using hazardous hydrogen gas. First attempts to develop 
asymmetric transfer hydrogenation date back to the 1970s and utilized rhodium and ruthenium phosphine 
complexes in the presence of enantiopure carbohydrates as a hydride source.2 However, these catalytic 
systems afforded only modest enantioselectivities. Since then, many types of homogenous asymmetric 
transfer hydrogenation catalysts mainly based on transition metal complexes of Ru(II), Rh(III) and Ir(III) 
have been reported. The most active and selective catalysts available nowadays are those contain 
bisphosphonites 13, pyridine derivatives 24, aza-norbornyl alcohols 35, amino alcohols 46 and tosylated 
diamines 57 (TsDPEN, N-tosyl 1,2-diphenyldiamine) (Figure 2.1).  
 
Fig. 2.1. Selected ligands used in asymmetric transfer hydrogenation. 
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The ruthenium η6-arene piano-stool complexes of TsDPEN developped by Noyori and related catalysts 
such as [(η5-Cp*)M(TsDPEN)Cl] (M = Rh, Ir; Cp* = pentamethyl cyclopentadienyl)8 are maybe the most 
prominent examples in this context. In presence of isopropanol or a formic acid/triethylamine azeatrope as 
a hydride source, these catalysts reduce aromatic ketones9, acetylenic carbonyl compounds10 and imines 
(see below) with high enantioselectivities. The generally accepted mechanism for the reduction of ketones 
by [(6-benzene)Ru(S,S-TsDPEN)Cl] is shown in Figure 2.211. Upon formal loss of HCl, the precatalyst 1 
forms a planar 16 electron amido complex 2 which reacts readily with isopropanol to yield the tetrahedral 
18 electron Ru-hydride species 3. The bifunctional constitution of the catalyst then promotes the concerted 
delivery of the hydride and a proton provided by the amine group of the ligand to the carbonyl moiety of 
the substrate via a six-membered transition state 4, thereby yielding the alcohol and regenerating the 16 
electron complex. This process occurs with an outer-sphere mechanism whereby neither the ketone 
substrate nor the alcohol interacts with the metallic center throughout the reduction. Studies by Wills 
showed that corresponding complexes in which the amino group of TsDPEN is alkylated are poor transfer 
hydrogenation catalysts, thus confirming the functional role of the ligand.12  
The hydride complex is sterically controlled by the enantiopure ligand, resulting in the formation of a single 
diastereomer that is chiral at Ru. Thereby, two structural features of the catalyst are responsible for the 
chiral induction. The enantiodiscrimination of the prochiral faces of the aromatic ketone depends on i) the 
chiral geometry of the five-membered chelate which determines the absolute configuration of the metal and 
ii) is mediated by an energetically favorable CH/-interaction between a hydrogen atom of the η6-arene and 
the aromatic moiety of the substrate.13   
It should be noted that recent computational studies by Ikariya suggest that the above mechanism is only 
valid in the gas-phase.14 Under consideration of solvation effects, calculations based on density functional 
theory suggest that the reaction proceeds in two steps whereby the enantioselectivity determining hydride 
transfer to the carbonyl moiety is followed by protonation of the resulting alkoxide. The proton source for 
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the latter process is probably a protic solvent molecule rather than the amine moiety of the ligand. This 
would imply that the catalytic cycle does not proceed necessarily via a 16 electron amido complex. 
 
 
Fig. 2.2. Suggested catalytic cycle of the asymmetric transfer hydrogenation of acetophenone with [(6-
benzene)Ru(R,R-TsDPEN)Cl]. According to recent studies by Ikariya, this mechanism may only be valid in the gas 
phase. 
 
2.1.1.2 Asymmetric Transfer Hydrogenation of Imines 
In contrast to asymmetric transfer hydrogenation of ketones, this reaction is relatively undeveloped for the 
reduction of imines. In 1996, Noyori showed that [(η6-arene)Ru(S,S-TsDPEN)Cl]-catalysts effectively 
reduce imines in the presence of a 5:2 formic acid-triethylamine azeotropic mixture in acetonitrile, 
achieving up to 97 ee for the reduction of various isoquinolines.15 Thereby, the reactivity of the catalysts 
was found to be much higher towards imine reduction compared to ketone reduction.  
Two different mechanisms have been proposed for the asymmetric transfer hydrogenation of imines, 
namely a concerted outer-sphere mechanism similar to the one operating in ketone-reduction and an ionic 
pathway where the nitrogen of the imine is protonated prior to hydride delivery from the metal to the carbon 
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of the polarized C=N bond. So far, experiments supporting either one or the other mechanism have been 
reported. Bäckvall used the isolated hydride species [(6-p-cymene)Ru(S,S-TsDPEN)H] for the 
stoichiometric reduction of imines.16 The reaction proceeded only under acidic conditions or in the presence 
of Lewis acids, thus supporting an ionic mechanism as the activation barrier may be too high for the delivery 
of the hydride to the non-protonated imine. This result contrasts with several other studies which suggest a 
concerted mechanism analogous to ketone reduction. Blackmond and coworkers performed kinetic 
experiments for the reduction of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline using [(5-Cp*)Rh(S,S-
TsDPEN)Cl] as a catalyst in presence of formic acid and triethylamine in methanol.17 According to this 
study, the reaction rates depend on the different acid-base equilibria between formic acid and the imine, the 
amine and triethylamine, respectively. Thereby it was suggested that the catalyst displays saturation kinetics 
towards the formation of the hydride inermediate even at low concentrations of formic acid and that the 
latter reactant protonates the imine substrate. Keeping the formic acid concentration low by slow addition 
during the reaction or performing the reaction at high triethylamine concentration, resulted in higher 
reaction rates whereby the formed Et3NH+HCOO--salt is thought to act as a reservoir for HCOOH. Based 
on these results, it was proposed that the free amine rather than the iminium was the actual substrate for the 
catalyst.  
As the opposite enantiomers are produced when compared to the reduction of prochiral alcohols, Wills 
suggested that the mechanism for the reduction of the imine substrate cannot be the same as the one for 
ketone reduction (Figure 2.3).18 Based on this hypothesis, he suggested two transition states which both 
lead to the observed enantiomers in the reduction of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 
using [(6-benzene)Ru(R,R-TsDPEN)Cl]: i) the imine is reduced via concerted six-membered transition 
state where the imine moiety is orientated relative to the catalyst in a way to allow a simultaneous delivery 
of hydrogen atoms to the C=N bond (Figure 2.3.C) ii) the imine is reduced by a ionic mechanism in which 
the C=N bond of the iminium is oriented away from the amine group of the ligand without adopting a six- 
membered transition state. This arrangement would allow the CH/π interaction observed in ketone reduction 
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to operate (Figure 2.3.D). However, experiments using N-alkylated R,R-TsDPEN derivatives to probe 
which of the two mechanisms is operative did not settle the question.  
 
 
Fig. 2.3. Proposed transition states for the transfer hydrogenation of imines using [(6-benzene)Ru(R,R-TsDPEN)Cl] 
suggested by Wills et al. A) concerted mechanism with a CH/-interaction between the arene of the catalyst and the 
aromatic moiety of the substrate for the reduction of acetophenone, yielding (R)-phenylethanol.  
B) the corresponding hypothetic transition state for the reduction of 6,7-dimethoxy-3,4-dihydroisoquinoline would 
afford the same absolute configuration of the product as in A which contrasts to the observed (S)-enantiomer. A 
plausible concerted non-ionic transition state without CH/-interaction (C) and a non-concerted ionic mechanism with 
CH/-interaction both deliver the observed (S)-product amine.18  
 
 
Further experiments addressing this issue were performed by Casey who applied a related bifunctional Ru-
catalyst ("Shvo's catalyst) to the transfer hydrogenation of imines.19 Whereas his detailed mechanistic 
investigations support a concerted mechanism, Bäckvall proposed a stepwise transfer of hydrogen atoms 
from this catalyst to the imine moiety whilst the nitrogen atom of the substrate is coordinated to the Ru-
center.20  
However, these examples show an ambiguous picture of the exact mechanism of the transfer hydrogenation 
of imines and illustrate the need for further investigations on this particular topic.   
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2.1.1.3 Asymmetric Transfer Hydrogenation in Water 
Asymmetric transfer hydrogenation in water has been reported for ketones as well as imines by various 
research groups using either Noyori type complexes or related catalysts of which some bearing modified 
ligands with improved water solubility (e.g. sulfonated TsDEPN).21 
Xiao and coworkers extensively investigated the pH-dependence of [(η6-p-cymene)Ru(R,R-TsDEPN)Cl] 
and [(η5-Cp*)M(TsDEPN)Cl] (where M = Rh, Ir) in the asymmetric transfer hydrogenation of ketones and 
imines in the presence of formate as a hydride source. Whereas the Ru-catalyst performed best at pH-values 
above 10 for the reduction of acetophenone22, the Rh and Ir counterparts display the highest activity and 
selectivity around neutral pH in ketone reduction23 and around pH 5 in imine reduction.24 At very acidic or 
basic conditions the performance of the latter catalysts was poor for both substrates. In the case of imine 
reduction this observation was traced back to two conflicting equilibria between the protonated and 
deprotonated forms of either formic acid and the imine substrate. At pH-values above 5.4, the fraction of 
protonated imine is low whereas at pH-values below 3.6 the concentration of formate decreases, on one 
hand leading to a lower concentration of reactive iminium and on the other hand resulting in a decreased 
rate at which the metal-formato complex and thus the hydride intermediate is formed. A pH-value between 
3.6 and 5.4 would be expected to afford high concentrations of both reactants and could therefore provide 
higher reaction rates. In addition, it was proposed that at low pH-values the nitrogen of the sulfonamide 
moiety of the TsDEPN ligand may be protonated and therefore dissociates from the metal. The resulting 
monodentate amine complex would be less ridgied and therefore may explain the poor enantioselectivity at 
low pH-values. Furthermore, it has to be considered that the hydride intermediate also may be protonated 
to yield H2 and that this competing reaction contributes to the low transfer hydrogenation activity under 
these conditions.25 
The low reaction rate at high pH-values may be explained by formation of the inactive hydroxo-species 
resulting from deprotonation of the corresponding cationic aquo-complex. The corresponding processes are 
outlined in Figure 2.4.    
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Fig 2.4. pH-dependence of asymmetric transfer hydrogenation in water.22 
 
 
 
 
 
2.1.2 Artificial Transferhydrogenases Based on the Biotin-(Strept)avidin Technology for the Asymmetric 
Reduction of Ketones (Previous Work) 
 
In a similar approach as applied for artificial hydrogenases (see section 1.1.2.2), a chemogenetic 
optimization strategy led to the development of artificial transferhydrogenases (ATHase) for the 
asymmetric reduction of ketones in the second half of the last decade within the Ward group. The chemical 
diversity of the racemic biotinylated Noyori-type catalyst [(ηn-Arene)M(biot-p-L)Cl] was generated by 
variation of the metal (M = RuII, RhIII, IrIII), the n = 6 (Arene = benzene, p-cymene, mesitylene, durene, 
hexamethyl benzene for M = Ru, n = 5 pentamethylcyclopentadienyl for M = Rh, Ir) and the substitution 
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pattern of the biotin moiety (q = ortho, meta, para) (figure 2.5).26 These complexes were prepared in situ 
from the corresponding metal precursors [(ηn-arene)MCl2]2 and the achiral ligands in refluxing isopropanol. 
Applying the twenty one resulting racemic metal complexes to the reduction of acetophenone, p-
bromoacetophenone and p-methylacetophenone in presence of streptavidin revealed that only the para-
substituted complexes afforded significant reaction products and that the capping arene had a great 
influence on the activity and selectivity of the ATHase. 
 
 
Fig. 2.5. Chemical diversity of the metal cofactor of the arificial transfer hydrogenase (ATHase). 
 
 
Docking studies of [(p-cymene)Ru(biot-p-L)H] within wild type streptavidin showed that the residues S112 
and S122 lie in closest proximity to the Ru-center. Nineteen streptavidin mutants resulting from saturation 
mutagenesis at position 112 were subsequently combined with a selection of five complexes (Ru in 
combination with either p-cymene, durene or benzene and Rh/Ir in combination with Cp*) and the resulting 
artificial metalloenzymes were tested in the reduction of the three acetophenone derivatives. The main 
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trends which emerged from this screening include: i) the absolute configuration of the reaction products is 
strongly dependent on the η6-arene present in the Ru-complexes whereas the induced selectivity of the 
corresponding ATHase can be reverted by the presence of cationic residues at position 112 (e.g. [(η6-p-
cymene)Ru(biot-p-L)Cl] yields (R)-phenylethanol with 90% ee in case of Sav-S112A and (S)-
phenylethanol with 20% ee when the S112K mutant is present). ii) the hybrid catalysts with Ru-complexes 
generally afford better results in terms of activity and selectivity compared to the Rh and Ir derived 
ATHases iii) ATHases with Sav-mutants offering a coordinating amino acid residue at position 112 (e.g. 
cysteine, histidine) are inactive, therefore confirming the proximity of this position to the metal center. The 
X-ray crystal structure of the most promising (S)-selective ATHase [(η6-benzene)Ru(biot-p-L)Cl]Sav-
S112K confirmed the proximity of the K112 residue to the metal-center and identified K121 of an adjacent 
monomer as another close-lying residue.27 In addition, L124 was found to display a close contact to the 
SO2-moiety of the ligand (figure 2.6). The absolute configuration of the Ru-atom is (S) which is also 
observed in the (S)-selective homogenous system with chiral TsDPEN-ligands. Based on these 
observations, a "second generation" of ATHases was designed by saturation mutagenesis of Sav-WT, Sav-
S112A (yields (R)-selective ATHases) and Sav-S112K (yields (S)-selective ATHases) at either the 121 and 
124 position. The resulting 120 Sav isoformes were combined with either [(η6-p-cymene)Ru(biot-p-L)Cl] 
or [(η6-benzene)Ru(biot-p-L)Cl] and tested for the reduction of different aromatic and dialkyl ketones. The 
screening revealed that the K121 position is more crucial to optimization of enantioselectivity whereby up 
to 90% ee for the reduction of was achieved using [(η6-p-cymene)Ru(biot-p-L)Cl]S112A-K121T. As the 
CH--interaction between p-cymene and the non-aromatic substrate cannot operate in this case, it was 
concluded that the selectivity is induced by the second coordination sphere of the host protein.   
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Fig. 2.6. Crystal structure of [(η6-benzene)Ru(biot-p-L)Cl]Sav-S112K (PDB-code:2QCB). Two symmetry-related 
monomers are highlighted in mangenta (monomer A) and cyan (monomer B). The metal cofactors and the closelying 
residues K112 and K121 are shown as sticks (carbon: grey, oxygen: red, nitrogen: blue, chlorine: green, Ru: cyan). 
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2.2 Artificial Transfer Hydrogenases based on the Biotin-(Strept)avidin 
Technology for the Asymmetric Reduction of Imines 
 
2.2.1 Preamble: Comment on Publications 
2.2.1.1 Optimization of an Artificial Transfer Hydrogenase for the Reduction of 6,7-dimethoxy-3,4-
dihydroisoquinoline 
Based on the results obtained previously for the ketone reduction, the ATHase system was tested for the 
asymmetric transfer hydrogenation of cyclic imines.  In order to identify suitable metal cofactors for this 
purpose, a selection of biotinylated d6 piano stool complexes have been screened in presence of WT-Sav 
for the reduction of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline to salsolidine in previous work. In 
contrast to ketone reduction, the [(η5-Cp*)M(biot-p-L)Cl] complexes (where M = RhIII, IrIII) afforded better 
results in terms of activity and selectivity than the corresponding [(η6-arene)Ru(biot-p-L)Cl] counterparts. 
For all but one metal complex the same absolute product configuration was observed for the reduction of 
phenylethanol and the imine substrate which contrasts with the corresponding homogenous system where 
aromatic imines and ketones are reduced with opposite selectivity, thus again illustrating the influence of 
the protein environment to the performance of the metal cofactors (see section 2.2.2).  
Control experiments indicated that the biotinylated complexes are localized within the biotin-binding site 
of the host protein and that it is the second coordination sphere which induces the selectivity of the artificial 
transfer hydrogenase: i) catalysis with [(η5-Cp*)Ir(biot-p-L)Cl] in absence of Sav affords (rac)-salsolidine, 
ii) racemic product in low yield was obtained with the non-biotinylated achiral counterpart [(η5-
Cp*)Ir(TsEN)Cl) in presence of Sav iii) addition of biotin decreases the selectivity of the artificial transfer 
hydrogenases drastically (see experimental part).  
The artificial transfer hydrogenase was genetically optimized for the transfer hydrogenation of 6,7-
dimethoxy-1-methyl-3,4-dihydroisoquinoline by screening a library of Sav isoforms resulting from 
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saturation mutagenesis at position S112 (see section 2.2.2). Similar trends with the mutant ATHases were 
observed as for ketone-reduction. [(η5-Cp*)Ir(biot-p-L)Cl]S112A (R-selective) and [(η5-Cp*)Ir(biot-p-
L)Cl]S112K (S-selective) provided the highest enantioselectivity and their performance could be further 
improved with respect to the reaction temperature and the Sav-tetramer/[Ir] ratio.  
 
 
2.2.1.2 Kinetics and Mechanism of the Artificial Transfer Hydrogenase  
HABA-titrations and circular dichroism (CD) spectroscopy where the biotinylated Ir-complex was added 
stepwise to a solution of Sav confirmed that the biotinylated complex is indeed incorporated within a well-
defined second coordination sphere. The maximal molar ration between [(η5-Cp*)Ir(biot-p-L)Cl] and 
tetrameric Sav was found to be 4:1 in both experiments, indicating that all four biotin-binding sites of the 
tetramer can accomodate the metal complex (see experimental part). Unfortunately, due to their complexity 
it was not possible to deconvolute the CD-spectra of [(η5-Cp*)Ir(biot-p-L)Cl]S112A and [(η5-Cp*)Ir(biot-
p-L)Cl]S112K to extract binding constants. 
The crystal structure of [(η5-Cp*)Ir(biot-p-L)Cl]S112A (see section 2.2.2) shows that the Ir-atoms of two 
adjacent monomers are located in close proximity (distance Ir····Ir = 5.2 Å) and therefore may interact 
during the catalytic process. Indeed, the molar ratio [(η5-Cp*)Ir(biot-p-L)Cl] vs. Sav-tetramer was found to 
have a great influence on the catalytic performance of the hybrid catalysts. In case of the S112A variant, a 
gradual erosion of the enantioselectivity was observed when increasing this ratio from 1:1 to 4:1 (where all 
biotin binding sites of the tetramer are occupied with the Ir-complex). In contrast, the enantioselectivity of 
the S112K-ATHase remains nearly constant. In case of both hybrid catalysts, the enantioselectivity 
decreases when an excess of complex is present which is due to the production of racemic product by 
unbound [(η5-Cp*)Ir(biot-p-L)Cl].  
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With regard to these observations, the following questions with respect to the mechanistic features of the 
hybrid catalysts arise: i) how do adjacent active sites of the Sav-tetramer influence each other during 
catalysis? ii) how is the enantioselectivity of the reaction induced? iii) what is the absolute configuration at 
Ir in [(η5-Cp*)Ir(biot-p-L)H] in the transition state? iv) which mechanism of the hydride transfer is operative 
(ionic or concerted)? 
To gain further information on how the enantioselectivity is induced in the S112A and S112K derived 
ATHases, the enzyme kinetics of [(η5-Cp*)Ir(biot-p-L)H] within both mutants at different [Ir]/Sav-tetramer 
ratios was determined (see section 2.2.3).  
A basic kinetic model of enzymes was developed by L. Michaelis and M.L. Menten.28 According to their 
underlying mechanism, the substrate (S) and the enzyme (E) form a complex (ES) in a first step (whereby 
k1 denotes the association rate and k-1 denotes the dissociation rate of ES). In a second step, the chemical 
transformation takes place with a first-order rate (k2) before the product (P) is released by the enzyme. 
Assuming that the second step is rate-limiting (k-1 ≫ k2), the enzyme-substrate complex ("Michaelis 
complex") is in thermodynamic equilibrium with free enzyme and substrate. 
 
whereby 
k1
k-1
= 
[E][S]
[ES]
 = Ks 
is the corresponding equilibrium constant. Since in biotransformations the concentration of the substrate is 
typically much higher than the concentration of the enzyme ([E] ≪ [S]), the concentration of the enzyme-
substrate complex remains constant during the reaction: 
d[ES]
dt
 = 0 
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This "steady-state" approximation formulated by G.E. Haldane and B.S. Briggs29 in 1925 is more general 
than the assumption of an equilibrium and the rate of an enzyme-catalyzed reaction can therefore be 
expressed with the Michaelis-Menten equation: 
v = 
Vmax + [S]
KM + [S]
 
Plotting the initial rate v against the substrate concentration [S] yields a hyperbolic curve indicating 
saturation kinetics with the maximal reaction rate at Vmax. In the case of the above mentioned Michaelis-
Menten mechanism in which only one particular enzyme-substrate complex is formed and all binding steps 
are fast, k2 represents the catalytic constant kcat which is defined as  
kcat = 
Vmax
[E]
0
 
where [E]0 is the total enzyme concentration ([E]0 = [E] + [ES]). kcat is often called the "turnover number" 
of an enzyme. However, since kcat is related to the number of conversions per time unit, it is actually the 
equivalent of the turnover frequency (TOF) used in context of homogenous catalysis.  KM denotes the 
Michaelis constant and represents the substrate concentration at which the rate v is equal to 1/2Vmax.  KM 
can be alternatively expressed as   
KM = 
k-1+ k2
k1
 = 
Ks+ k2
k1
 
If k-1 ≫ k2, the dissociation constant Ks of the Michelis-Komplex becomes equal to the Michaelis constant 
(Ks = KM). The Michaelis constant therefore can be viewed as a measure of the substrate affinity towards 
the enzyme.    
The assumption of interacting metal cofactors located in neighboring active sites is supported by the 
observation that the kcat values decrease upon raising the [Ir]/Sav-S112A ratio from 2:1 to 4:1 (see section 
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2.2.3). The significantly higher KM-value in the fully [Ir]-saturated ATHase suggests that the affinity of the 
substrate towards the artificial metal cofactor decreases, possibly due to sterical hindrance between two Ir-
Cp*-moieties. This interaction may also explain the observed concurrent decrease of the enantioselectivity, 
indicating a different second coordination sphere around the metal at high [Ir]/Sav-S112A ratios as the 
complex adopts a different conformation. In contrast, [(η5-Cp*)Ir(biot-p-L)Cl] seems to operate 
independently in case of the S112K mutant as the ee- and kcat-values remain constant upon increasing the 
[Ir]/Sav-S112A ratio from 1:1 to 4:1. The different behavior implies that the amino acid residue at position 
112 close to the active site dictates the conformation of the metal cofactor which in turn determines the 
relative alignment between the latter moiety and the substrate in the transition state and thus the absolute 
configuration of the amine product produced. 
With a critical look at the kinetic results obtained from catalysis at different [Ir]/Sav ratios, it has to be 
mentioned that incubation of [(η5-Cp*)Ir(biot-p-L)Cl] with Sav in case where this ratio is lower than 4:1 
results in a statistical distribution of Sav-tetramers with either no, one, two, three or four bound metal 
cofactors. Therefore, it may be likely that the concentration of Sav-tetramer at a certain ratio of complex 
and Sav might be slightly different as one would expect from the molar ratio which was obtained by 
applying a given relative concentration in the experiment. In addition, the obtained kinetic parameters (kcat, 
KM) are apparent constants as transfer hydrogenation involves the consumption of actually two substrates 
(imine and formate) to yield two products (amine and CO2). Therefore, this reaction might not be applicable 
per se to the Michaelis-Menten mechanism on which the respective kinetic law relies.     
Another question that arises in this context what is the absolute configuration of the metal center in the 
transition state of the reaction. The catalytic cycle of transfer hydrogenation involves a planar 16 electron 
complex to which the hydride can be delivered from both bottom and top face. Ikariya showed that prior to 
hydride formation formate binds to the metal in the 16 electron amido complex [(p-cymene)Ru(R,R-
TsNCHPhCHPhNH)] yielding the corresponding 18 electron formato complex as a single diastereomer.30 
This intermediate subsequently decarboxylates to afford enantiopure [(η6-p-cymene)Ru(R,R-TsDPEN)H] 
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and CO2. In the homogenous system the chiral ligand thus dictates the absolute configuration of the metal 
hydride which in turn determines the enantioselectivity in the reduction of the substrate (see section 2.1.1.1). 
In contrast, the Ir-center of [(η5-Cp*)Ir(biot-p-L)H] is not configurationally stable in absence of Sav as it 
affords racemic-at metal intermediate in the transfer hydrogenation. In principle, two possible 
enantioselectivity determining mechanisms may operate in the case of the ATHase which both may 
contribute to the enantiodiscrimination: i) the second coordination sphere of the host protein favors the 
formation of a single [(η5-Cp*)Ir(biot-p-L)H]-diastereomer which then induces the enantioselectivity 
similar to the homogenous system or ii) there is no influence of the second coordination sphere on the 
selectivity of the hydride formation but one of the two resulting ATHase-isomers (obtained from the 
combination of the racemic metal cofactor and the enantiopure protein) is more reactive towards the 
substrate. The situation becomes even more complex in case where the molar ratio of [Ir]/Sav-tetramer is 
greater than 1:4 as more than two isomers exist. The finding that only one configuration of the metal center 
is observed in the crystal structure of [(η5-Cp*)Ir(biot-p-L)Cl]S112A (see section 2.2.2) suggests that the 
host protein discriminates between two diastereomers of [(η5-Cp*)Ir(biot-p-L)H] and therefore it seems 
unlikely that different diastereoisomers of the hybrid catalyst are formed. This leads to the hypothesis that 
the protein environment in ATHases dictates the absolute configuration of the metal in [(η5-Cp*)Ir(biot-p-
L)H]. The observation that the enantioselectivity of the reaction decreases above [Ir]/Sav ratios of 2:1 in 
the case of the S112A-ATHase may thus indicate that metal complexes located in adjacent acive sites of 
the Sav-tetramer may influence each other when the absolute configuration at Ir is determined. This is not 
the case in the S112K counterpart as the individual active sites operate independently. The resulting 
"induced key-and-lock" mechanism is not only supported by the Michaelis-Menten behavior (see above) 
but also by additional data obtained from the crystal structure of the S112K-ATHase as well as docking 
studies and is discussed in detail in section 2.2.3.              
Further investigations concerning the question if an ionic or concerted mechanism is operative in the 
ATHase-mediated transfer hydrogenation are presented in section 2.2.4.                     
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2.2.2 Artificial Transfer Hydrogenases for the Enantioselective Reduction of Cyclic Imines 
 
 
Author contribution: synthesis of biotinylated metal complexes, screening of Sav mutants (in collaboration 
with Annette Mutschler), optimization of the reaction conditions for [(η5-Cp*)Ir(biot-p-L)Cl]S112A, 
HABA-assays 
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2.2.3 Structural-, Kinetic- and Docking Studies of Artificial Imine Reductases Based on the Biotin-
Streptavidin Technology: An Induced Lock-and-Key Hypothesis 
 
 
 
Author contributions: Michaelis-Menten kinetics of [(η5-Cp*)Ir(biot-p-L)Cl]S112A and [(η5-Cp*)Ir(biot-
p-L)Cl]S112K for the transfer hydrogenation of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline, 
catalysis  
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2.2.4 Appendix 
 
The crystal structure of [(η5-Cp*)Ir(biot-p-L)Cl]S112A revealed that the absolute configuration of Ir is 
(S) which yields (R)-[(η5-Cp*)Ir(biot-p-L)H] upon reaction with formate. Based on this finding, a non-
concerted mechanism was suggested for the hydride transfer whereby a CH- interaction between Cp* and 
the aromatic moiety of the substrate is operating (see section 2.2.2). In addition, it was hypothesized that 
the lysine-residue K121 of an adjacent monomer may be involved in the protonation of the imine nitrogen. 
Further experiments were performed to examine if this lysine residue serves as a proton-donor, namely the 
determination of the pKa-value of the imine substrate and kinetic studies of the double-mutant S112A-
K121T in which the critical lysine residue is replaced by threonine.  
 
 
2.2.4.1 pKa of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 
The behavior of cyclic imines in aqueous solution may be described by three equilibrium constants: a 
hydrolysis constant KH which describes the hydrolysis of the C=N bond and two acid-base equilibrium 
constants which describe the protonation of either the imine (K1) or the open-chain amino ketone (K2)31:  
 
 
Figure 2.7 Possible equilibria of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline in water. 
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The titration of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline with HCl resulted in a typical sigmoidal 
titration curve with a corresponding pKa of approximately 8.5, indicating the existence of a single 
equilibrium. Two dimensional NMR-experiments (HMBC) performed in water indicate that the imine 
substrate exists exclusively in its ring-closed form under acidic (pH 2.5) as well as basic (pH 11.5) 
conditions (see experimental part). This somehow unexpected result may be explained by an unfavorable 
loss of entropy upon hydrolysis. The chemical shifts obtained for selected 1H and 13C signals at different 
pH-values between 3 and 11 allowed to locate the pKa1 within a range of 8.5-9 which is in good agreement 
with the value obtained from the titration (see experimental part).      
 
 
2.2.4.2 Michaelis-Menten Kinetics of [(η5-Cp*)Ir(biot-p-L)HS112A-K121T 
If the lysine residue K121A of the adjacent Sav-monomer would act as a proton donor in the transfer 
hydrogenation process of [(η5-Cp*)Ir(biot-p-L)H]S112A, one would assume that replacing this residue 
by another polar amino acid downgrades the performance of the resulting double mutant. Indeed, [(η5-
Cp*)Ir(biot-p-L)H]S112A-K121T showed an erosion of enantioselectivity compared to the S112A-
counterpart (see section 2.2.2). To find out if the double mutant as well displays a lower activity towards 
the transfer hydrogenation of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline, the Michaelis-Menten 
kinetics of this ATHase isoform was determined (see section 2.2.3 for a detailed experimental procedure). 
As observed for the S112A-ATHase, the activity of the metal cofactor within the double mutant decreases 
when raising the molar ratio [Ir]/Sav-tetramer from. Comparison of the kinetic profiles of [(η5-Cp*)Ir(biot-
p-L)H] within the two variants did not show a significant difference in activity as similar kcat-values were 
observed (kcat = 14.1 and 11.4 min-1 in case of S112A vs. kcat = 11.5 and 9.7 min-1 in case of S112A-K121T). 
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Figure 2.8 Michaelis-Menten plots of [(η5-Cp*)Ir(biot-p-L)H]Sav-S112A-K121T (left) and [(η5-Cp*)Ir(biot-p-
L)H]Sav-S112A (right, see section 2.2.2) for the transfer hydrogenation of 6,7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline. The color scheme represents kinetic profiles at different molar ratios of the Ir-complex versus 
free Sav biotin binding sites: blue trace 0.25 eq [Ir], red trace 0.5 eq [Ir]. Initial rates were plotted with respect to the 
concentration of the Ir-complex. The concentration of Sav free biotin binding sites was 100 M.      
  
 
In conclusion, these results on one hand support that an ionic, non-concerted mechanism is operative in the 
transfer hydrogenation of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline catalyzed by [(η5-Cp*)Ir(biot-
p-L)Cl]S112A as the imine nitrogen seems to be protonated under the experimental conditions (typically 
pH 6.5-7.5). Both the activity and selectivity of the S112A-ATHase decrease significantly above pH 8 (see 
experimental part). This behavior is not necessarily explained by a decreased fraction of the protonated 
imine as other processes such as deprotonation of amino acid residues of Sav may have an influence on the 
performance of the hybrid catalyst.  
The functional role of lysine 121K could not be confirmed as its absence does not decrease the reaction rate 
with respect to the S112A-K121T isoform. However, when comparing the two ATHase variants it has to 
be considered that additional beneficial effects (e.g. structural changes) may have an impact on the activity 
of the double mutant ATHase which counterbalance the possible reduced activity caused by the absence of 
the lysine residue.  
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2.3 Conclusions and Outlook  
 
 
The substrate scope of artificial transfer hydrogenanses based on the biotin-(strept)avidin technology could 
successfully be expanded from the reduction of ketones to cylic imines. The introduction of a biotinylated 
iridium pianostool complex [(η5-Cp*)Ir(Biot-p-L)Cl] within streptavidin affords an artificial imine 
reductase which was optimized by saturation mutagenesis at position 112. Thereby, both enantiomers of 
the corresponding imine are accessible using the same organometallic moiety, affording 96% ee in favor of 
the (R)-enantiomer in case of [(η5-Cp*)Ir(Biot-p-L)Cl]S112A and 78% ee in case of [(η5-Cp*)Ir(Biot-p-
L)Cl]S112K for the production of salsolidine.  
Although the observed Michaelis-Menten behavior may rely on a simplified mechanistic model, the 
obtained kinetic parameters in combination with structural data and docking studies allowed to establish a 
qualitative model of the mode of action of these hybrid catalysts. Nevertheless, the role of the formate 
concentration should be investigated in prospective kinetic studies. 
The high robustness and activity of the ATHases (up to 4000 TON could be achieved) renders them to ideal 
candidates for laboratory evolution protocols. This procedure eventually may allow to further optimize 
ATHases in order to identify catalysts for the enantioselective reduction of more challenging substrates.   
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Chapter 3: Towards in vivo Transition Metal Catalysis and its 
Potential Applications for the Directed Evolution of Artificial 
Metalloenzymes 
 
 
 
3.1 Introduction 
 
3.1.1 Principles of Directed Evolution   
 
The outstanding catalytic properties of enzymes result from natural selection which is the "driving force" 
of evolution. The introduction of mutations may lead to improved or even new catalytic functions which 
will survive if the related enzyme provides a beneficial feature to the host organism with respect to its 
adaptability to a particular environment ("survival of the fittest"). Evolution of life therefore can be seen as 
a random "trial-and-failure" process which selects for the fittest. In contrast, laboratory evolution protocols 
have a defined goal in order to improve certain properties of an enzyme such as its stability (e.g. towards 
the presence of organic solvents), activity and selectivity (e.g. towards non-native substrates).1 Apart from 
this important difference, directed evolution protocols mimic Darwinian evolutionary processes by 
performing iterative cycles of mutagenesis and identifying mutants with desired properties. A typical 
experimental cycle of directed evolution is given in Figure 3.1. Starting point is an enzyme with a desired 
activity that is wished to be increased or modified. In a first step, sequence diversity is created by 
mutagenesis of the corresponding DNA sequence. Given the 20 standard proteinogenic amino acids, a 
protein with an average number of 250 residues gives rise to 20250 possible combinations. Even if only a 
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small part of the resulting proteins is functional, a great variety of structures and functionalities can be 
obtained.2 Mutations can either be introduced at certain positions in the primary structure using site-directed 
mutagenesis (e.g. to replace amino acid residues close to the active site) or throughout the entire gene using 
random mutagenesis (e.g. by error-prone mutagenesis).3 Additional diversity may be generated by 
techniques which recombines homologues DNA fragments to generate new genes such as DNA shuffling4 
or RACHITT (random chimeragenesis on transient templates).5 After the mutated genes have been cloned 
into an expression vector and transformed into a suitable host bacterium, the activity of the expressed 
enzyme variants is determined either by high-throughput screening (HTS)6 or selection.7  The advantage of 
screening is that the enzymatic reaction can eventually be detected directly in the cell cultures or on agar 
plates. The simplest approach in this context includes visual screens in which the enzymatic reaction 
generates a product of a different color from the starting material (e.g p-nitrophenyl derivatives to monitor 
hydrolase activity).8 In cases where no chromogenic substarte is available for a particular enzyme, other 
methods such as high performance liquid chromatography (HPLC),9 nuclear magnetic resonance (NMR),10 
mass spectromerty (MS),11 gas chromatography (GC),12 circular dichroism (CD)13 or fluorescence assisted 
cell sorting (FACS)14 etc. have been applied for HTS purposes. However, the major drawback of screening 
is that each individual clone has to be tested for a desired enzymatic transformation, including those which 
do not provide a functional biocatalyst. In contrast, selection uncovers only mutants of interest. The 
principle relies on the circumstance that bacteria experience an advantage in survival if a particular 
catalyzed transformation produces an essential nutrient that the corresponding cell strain cannot produce 
itself (auxotrophy)15 or degrades a toxic compound.14,16 Growth of single bacterial clones in a medium 
containing a corresponding precursor or a toxin thus indicates the expression of a highly active enzyme 
variant ("chemical complementation"). If a given enzymatic reaction allows to apply a selection 
mechanism, it is usually the method of choise as up to 1013 mutants can be analysed whereas screening 
limits the size of the library to about 104 variants.17 Independently of which methododology is used, the 
consistence of the corresponding model substrate should be as similar as possible to the target substrate 
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which is desired to convert with the evolved biocatalyst ("you get what you select/screen for").18 Many 
laboratory evolution protocolls therefore often do not lead to the desired result.  
Nevertheless, directed evolution has a great potential to improve particular features of enzymes without the 
need to know their molecular structure and has been applied successfully to increase the thermal stability,19 
the stability towards organic solvents,20 the oxidative stability,21 the alkaline tolerance,22 and the selectivity 
as well as the activity towards non-native substrates.23 
 
 
 Fig. 3.1. Schematic outline of the directed evolution procedure. Colored dots indicate different mutations. 
 
 
3.1.2 Directed Evolution of Artificial Metalloenzymes 
The artificial metalloenzymes reported so far by various reserach groups generally perform as effectively 
as their homogenous counterparts at best. As outlined in chapter 1, the actual potential of these hybrid 
catalysts lies in the high tuneability of the respective host protein by means of genetic diversification of the 
second coordination sphere. Although considerable improvement has been achieved by rational design (see 
chapter 1), directed evolution protocols for artificial metalloenzymes are highly desirable as a much higher 
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number of variants can be obtained. This technology was applied successfully to numerous biocatalysts 
used in academic laboratories and industry.24 In contrast, to date only one proof-of-principle approaches 
have been reported to expand directed evolution to hybrid catalysts.  
Reetz and coworkers used a "laboratory evolution protocol" to improve the enantioselectivity of an artificial 
hydrogenase based on the biotin-(strept)avidin technology towards the reduction of -acetamido-acrylic 
acid methyl ester.25 Selected residues in proximity of the active site were randomized specifically in an 
iterative manner by applying CAST (combinatorial active site saturation test). The corresponding positions 
were identified by modelling the biotinylated Rh(I)-diphosphine complex into the X-ray crystall structure 
of streptavidin-biotin and comprise residues close to the metal center which directly influence the 
conformation of the metal cofactor-substrate complex as well as more distant amino acids potentially 
having an impact on the protein structure as they are involved in hydrogen bondings of secondary elements. 
In each saturation mutagenesis experiment about two to three hundred clones were tested in the 
hydrogenation, thereby covering >95 % of all possible mutants. Saturation mutagenesis was performed at 
positions 110, 112 and 124, leading to the artificial hydrogenase variant Sav-S112G which displays a 
slightly improved (R)-enantioselectivity (35% ee) compared to the wild type enzyme (23 % ee). Two further 
rounds of saturation mutagenesis resulted in the N49V isoform, providing the hydrogenated product in 65% 
ee. 
 
Fig. 3.2. Benchmark reaction for the directed evolution of an artificial hydrogenase reported by Reetz et al.25   
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Although the modest selectivity of the final artificial hydrogenase variant is far lower than one would expect 
for from such an evolutionary approach, this study is noteworthy as it shows that directed evolution in 
principle can be applied to hybrid catalysts and illustrates the challenges that arise by doing so. The poor 
result can partially be explained with the fact that only a relatively small library of Sav-isoforms could be 
employed which is traced back to the poor expression levels of some mutants. This restricts the the 
screening effort as the bacteria cultures become to large to produce thousands of mutants in parallel (e.g. in 
microtiter plates). In contrast to natural enzymes, chemical catalysts exhibit lower catalytic activities and 
therefore larger amounts of protein is required when performing directed evolution of hybrid catalysts. In 
this context it has also to be considered that the amount of protein cannot be determined for each mutant 
when generating very large protein libraries and therefore the metal cofactor may be present in an excess 
compared to the host. Since in this case the outcome of the catalysis would be biased, it has to be ensured 
that the incorporated metal cofactor is significantly more active than the free one (e.g. through a ligand 
exchange within the protein scaffold) or that the free metal complex is inactive (e.g. by the presence of an 
inhibitory ligand that has no access to the protein-embeded metal). Furthermore, catalysis should ideally be 
performed in crude cell extracts or in living cells. This on one hand avoids the time-consuming purification 
step of the mutant proteins which significantly expands the size of the library that can be screened. On the 
other hand, the use of living cells allows to apply selection to identify high-performance (hybrid) catalysts. 
Although not explicitly stated by Reetz and coworkers, it is likely that the Sav-mutants were -at least 
partially- purified before being subjected to catalysis. However, performing transition metal catalysis in 
living systems is indeed a challenging task as the presence of cellular metabolites significantly reduces the 
activity of the corresponding catalysts and therefore may be the major hurdle when evolving artificial 
metalloenzymes in a Darwinian approach.26         
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3.2 Towards in vivo Transition Metal Catalysis 
 
3.2.1 Preamble: Comment on Publications  
In order to perform directed evolution of artificial transfer hydrogenases or apply organometallic chemistry 
in context of synthetic biology, the activity of the corresponding catalyst in presence of cellular environment 
has to be ensured. Furthermore, it has to be considered that the catalyst may interact with different cellular 
components and therefore displays toxic effects which affect the viability of the cell.   
With the aim of performing in vivo transition metal catalysis, two main challenges have been identified. 
First, thiols mainly present in the form of glutathione may inactivate the catalyst. Second, the cellular 
proteins and metal complexes often suffer from mutual inhibition. This chapter summarizes the efforts to 
overcome these challenges and presents two possible selection systems which may be applied in the directed 
evolution of artificial transfer hydrogenases. 
 
3.2.1.1 Neutralizing the Detrimental Effect of Glutathione on Precious Metal Catalysts 
Glutathione (γ-L-Glutamyl-L-cysteinylglycine, GSH) is a one electron donor which among other functions 
serves as a scavenger of reactive oxygen species (ROS) whereby it is oxidised to dimeric glutathione 
disulfide (GSSG).27 Due to its high cytosolic concentration (up to 17 mM!),28 glutathione is one of the main 
source of free thiol groups and therefore may contribute significantly to the poisonning of soft transition 
metal catalysts within the cell. Indeed, addition of GSH severely inhibits the catalytic performance of [(η5-
Cp*)Ir(Biot-p-L)Cl] as well as the respective hybrid catalysts [(η5-Cp*)Ir(Biot-p-L)Cl]S112A and [(η5-
Cp*)Ir(Biot-p-L)Cl]S112K and no activity towards the reduction of 6,7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline was observed. Subsequently, a selection of oxidizing agents and Michael acceptors 
known to react with the thiol group of GSH were tested to neutralize the detrimental effect of GSH on the 
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precious metal catalyst. This screening was performed using purified Sav in reactions spiked with GSH and 
led to the identification of some promising "GSH-neutralizing" reagents. Among these, Diamide (1,1'-
azobis(N, N-dimethylformamide)) proved to be efficient as well in E. coli cell free extracts (cfe) and cell 
lysates containg Sav-mutants. Thereby, the presence of Sav turned out to be beneficial for the catalytic 
performance of [(η5-Cp*)Ir(Biot-p-L)H], affording up to 110 TON in cfe and 86 TON when cell lysate was 
used as a source of Sav. The results are summarized in section 3.2.2.   
 
 
3.2.1.2 Preventing Mutual Inhibition between Organometallic Catalysts and Cellular Proteins by the Use 
of Artificial Metalloenzymes 
Mutual inhibition between organometallic catalysts and enzymes is a phenomen which is often observed 
when combining these two catalytic systems to establish reaction casacades. This may be traced back to 
interactions beween the metal and functional groups of certain amino acids on the surface of proteins.29 
With the aim of performing catalysis in vivo, this challenge was adressed in a biomimetic manner. The 
incorporation of [(η5-Cp*)Ir(Biot-p-L)H] within Sav shields the organometallic moiety and thus prevent 
inhibitory interactions with natural enzymes. This concept was tested in a benchmark reaction which 
combined the artificial transfer hydrogenase with evolved monoamine oxidases (MAO) from Aspergilus 
niger to perform concurrent double stereoselective deracemisation of amines. Thereby, the artificial transfer 
hydrogenase reduces the imine with moderate (R)-selectivity whereas the minor (S)-amine is converted 
back to the imine by the highly selective MAO. After several cycles of this process, the (R)-amine 
accumulates up to 99% ee. To prevent deactivation of the Ir-catalyst by hydrogen peroxide generated 
through the catalytic action of MAO catalase was added to the reaction to decompose this side product. 
This procedure was successfully applied to several substrates, including 1-methyl-3,4-dihydroisoquinoline, 
2-cyclohexyl-1-pyrroline and pseudooxynicotine. The corresponding artificial transfer hydrogenase 
variants were identified with a screening of Sav-mutants for each substrate. The obtained results indicate 
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that the artificial transfer hydrogenase may also be a promising catalyst for the reduction of aliphatic imines 
as up to 86% ee was achieved for the reduction of 2-cyclohexyl-1-pyrroline.  
A time plot of the concurrent deracemisation of 1-methyl-3,4-dihydroisoquinoline demonstartes that in the 
presence of the (R)-selective artificial transfer hydrogenase variant [(η5-Cp*)Ir(Biot-p-L)Cl]S112T a high 
enantomeric excess is more rapidly reached as when the (S)-selective artificial transfer hydrogenase [(η5-
Cp*)Ir(Biot-p-L)Cl]S112K was used. The saturation kinetics of these artificial transfer hydrogenase 
isoforms revealed that [(η5-Cp*)Ir(Biot-p-L)Cl]S112K actually displays a higher kcat value than the 
S112T counterpart but on the same time has a lower affinity for the substrate as reflected by the higher 
Michaelis constant KM. In addition, the S112T-ATHase was found to be prone to significant substrate 
inhibition. This phenomen is also observed with natural enzymes at high subbstrate concentrations and can 
be explained with the binding of a second substrate molecule in the active site. 
 
whereby Ki is the dissociation equilibrium constant 1/KN for the reaction SES S + ES.30 
The kinetic profile of the cascade reaction thus can be explained with a combined effect of these kinetic 
parameters and the selectivity of the ATHases. 
Encouraged by these results, the ATHase was used within a more complex reaction cascade and combined 
with amino acid oxidases. The S112A-ATHase reduces 1-piperidine-2-carboxylic acid generated in situ 
from L-lysine by the enzyme L-amino acid oxidase (LAAO) from snake venom (Crotalus atrox), yielding 
L-pipecolic acid with moderate enantioselectivity. The latter could be upgraded by addition of a D-amino 
acid oxidase from pig liver which oxidizes the minor D-pipecolic acid to 1-piperidine-2-carboxylic acid. 
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Again, addition of catalase prevents the deactivation of the metal cofactor by H2O2 produced by both amino 
acid oxidases, thus combining the ATHase with three natural enzymes which display complementary and 
compatible catalytic properties for the production of L-pipecolic acid. 
In all presented casacade reactions herein the presence of Sav is crucial to prevent mutual inhibition between 
the organometallic catalyst and the enzymes. The absence of the host protein leads typically to lower 
conversions and/or to racemic product. The herein presented strategy thus represents an efficient approach 
to overcome the incompatibility of both homogenous and bio-catalysts and moreover may allow to perform 
transition metal catalysis in living cells.         
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3.2.2 Synthetic Cascades are Enabled by Combining Biocatalysts with Artificial Metalloenzymes  
 
Author contribution: Screening of ATHase isoforms for the reduction of 1-methyl-3,4-dihydroisoquinoline 
and 2-cyclohexyl-1-pyrroline, performing the cascade reactions with 1-methyl-3,4-dihydroisoquinoline, 2-
cyclohexyl-1-pyrroline, pseudooxynicotine and lysine (in collaboration with Valentin Köhler), kinetic 
measurements with the ATHase isoforms for the transfer hydrogenation of 1-methyl-3,4-
dihydroisoquinoline. 
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3.2.3 Neutralizing the Detrimental Effect of Glutathione on Precious Metal Catalysts        
 
 
Author contribution: all experiments were performed in collaboration with Yvonne M. Wilson and Elisa 
S. Nogueira. 
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3.2.4 Appendix 
When considering directed evolution of protein-derrived catalysts (i.e. enzymes or hybrid catalysts), a 
suitable method has to be identified which allows to detect the catalytic activity of the desired 
transformation for a large number of mutants. Two strategies are usally applied for this purpose: high-
throughput screening and selection (see section 3.1.1.1). In the case where catalysis is performed in living 
cells, the latter methodology can be used to screen for catalytic activity.  
Two reactions were devised which may be applied in a selection mechanism for the directed evolution of 
ATHases and their feasibility was tested in context of initial experiments. Both approaches rely on the 
reduction of 1,4-unsaturated carbonyl compounds. Several studies showed that transfer hydrogenation is an 
effective catalytic method for this purpose.30 Additionally, prior studies within the Ward group revealed 
that enones are suitable substrates for ATHases.31 However, as the corresponding transformations are not 
enantioselective they serve only as a method to screen for ATHase activity.  
 
3.2.4.1 ATHase-mediated Generation of Amino Acids from Enone Precursors 
Two amino acid precursors were synthesized, namely 1 and 3 (see experimental part for a detailed synthetic 
procedure). The 1,4-reduction of these compounds yields the corresponding saturated -keto acids 2a and 
4a which may be prone to transamination by intracellular transaminases, thus affording leucine and valine 
(Figure 3.3). In a quantitative reaction (25 mg), both compounds were subjected to transfer hydrogenation 
using 1 mol% [(η5-Cp*)M(Biot-p-L)Cl] (M = Rh, Ir) and 2 equivalents of sodium formate (100 mM) within 
a period of 10 hours. The 1H-NMR-spectra of the isolated product mixtures revealed that transfer 
hydrogenation of 1 yielded the unsaturated hydroxylic acid 2b (approximately 25% yield) whereas the 
desired unsaturated product 2a resulting from 1,4-reduction was not detected. In contrast, reduction of 3 
produced almost exclusively the desired -keto acid 4a in near quantitative yield. Thereby, the Rh-catalyst 
seems to be slightly more selective with respect to 1,4-reduction as no alcohol formation could be observed 
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whereas in case of the Ir-complex traces of the fully reduced compound 3c was detected. The lower 
reactivity of 1 results possibly from the increased steric demand of this substrate.  
Inital experiments with some Sav-mutants showed that compound 3 is also reduced by [(η5-Cp*)M(Biot-p-
L)Cl] when incorporated in the host protein at low formate concentrations. As judged from GC-traces, in 
all cases the valine precursor 4a was found to be one of the main products. However, further conclusions 
concerning the dependence of the Sav-mutant on the chemoselectivity of this reaction are hard to be drawn 
as additional peaks in the GC-spectra corresponding to unidentified compounds were present and the used 
analytical GC-method did not allow to quantify the (derivatized) reaction products. Further experiments 
showed that the valine precursor 4a is indeed transaminated in presence of E. coli cell free extracts. 
However, attempts to generate valine with the ATHase in presence of cell free extracts failed so far.     
            
 
Fig. 3.3. ATHase mediated generation of amino acid precursors as a selection strategy. 
 
 
 
140 Chapter 3: Towards in vivo Transition Metal Catalysis 
3.2.4.2 ATHase-mediated Degradation of an Antibiotic 
Bacteria expressing a Sav-mutant that in combination with the artificial metal cofactor provides an efficient 
hybrid catalyst for the degradation of an antibiotic would experience an advantage to survive in presence 
of the drug. Based on this idea fluoroquinolines were tested as substrates of the ATHase. Members of this 
antibiotic class inhibits two essential enzymes (DNA-gyrase and topoisomerase IV) associated with the 
replication of the bacterial genome and is widely used to treat infections of various gram-negative bacteria 
including E. coli.32 The structural core element of all fluoroquinolons exhibits an enone moiety prone to 
1,4-reduction by reactive hydride species.33 The resulting intermediate decarboxylates spontaneously to 
yield an inactive form of the antibiotic as reflected by the much higher minimal inhibitory concentrations 
(MIC) of this derivative, thus providing a potential selection mechanism.34 As a color change to yellow 
occurs uppon reduction, this system on the same time may afford a screening method for the ATHase 
activity. However, initial results with purified protein showed modest activity of different ATHase-variants 
based on [(η5-Cp*)M(biot-p-L)Cl] (M = Rh, Ir) towards Enrofloxacin (see experimental part). 
 
 
 
 
Fig. 3.4. ATHase-mediated degradation of fluoroquinoline antibiotics as a potential selection mechanism. 
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Further studies in collaboration with Seraina Blümli (master thesis) revealed that catalysts obtained from 
combination of the biotinylated metal precursor [η5-Cp*biotIrCl2]2 with different bidendate ligands as well 
as the respective ATHase variants are more active towards the reduction of this particular substrate, 
achieving up to 50 TON in case of the K121A-variant (see figure 3.5).35 Additionally, a colorimetric assay 
could be developped which allows to monitor the reaction in a parallel manner.  
     
 
Fig. 3.5. "Second generation" transfer hydrogenation catalyst displaying improved catalytic activity towards the 
reduction of Enrofloxacin within Sav-mutants. The catalyst was prepared in situ from [η5-Cp*biotIrCl2]2 and 1-amino 
cyclopentane carboxmide.35 
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3.3 Conclusions and Outlook 
 
 
The implementation of a directed evolution protocol for artificial metalloenzymes may further tune these 
hybrid catalysts and therefore is highly desirable. However, this implies the performance of transition metal 
catalysis in a cellular environment. Artificial transfer hydrogenases based on the biotin-(Strept)avidin 
technology for the enantioselective reduction of imines served as a corresponding model system to adress 
two major issues in this context. First, the incorporation of a homogenous metal catalyst within a host 
protein effectively prevents mutual inhibition between the organometallic moiety and several natural 
enzymes. Second, an effective reagent was identified to neutralize the dentrimetal effect of glutathione on 
precious metal catalysts.  
Further efforts include the realization of in vivo catalysis. For this purpose, the integrity of the cell has to 
be ensured. Initial experiments indicate that the reaction conditions under which the ATHase operates for 
the reduction of imines are not compatible with bacterial cells (in particular the high formate 
concentrations). Cell lysis was observed within a short period of time when incubated with the 
corresponding reaction buffer. Therefore, enones may be more suitable substrates as it was illustrated that 
some of these compounds are reduced more effectively at much lower formate concentrations. 
Alternatively, a formate-independent reaction could be applied. Ikariya showed that [(-arene)Ru(R,R-
TsDPEN)] complexes catalyse the enantioselective 1,4-addition of malonates to enones.37 
In addition, the uptake of the metal cofactor into the cell has to be ensured. Otherwise, an expression system 
has to be developped where the Sav-mutants are displayed on the cell surface or are secreted into the growth 
medium. However, respective systems are under investigation currently within the Ward-group. 
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Chapter 4: Experimental Part 
 
 
 
4.1 General Information 
 
4.1.1 Reagents and Solvents 
Commercial reagents were purchased at the highest degree of purity available and used without further 
purification. For analytical high performance liquid chromatography (HPLC) solvents with a corresponding 
HPLC-grade were used. Buffers were prepared with MiliQ-grade water obtained from a Barnstead ultrapure 
water system. 
 
4.1.2 Materials 
For thin layer chromatography Merck silica gel 60 F254 plates were used. Flash chromatography was 
performed with Merck silica gel 60 (particle size 40-63 mm). 
 
4.1.3 Analytical Methods 
4.1.3.1 Nuclear Magnetic Resonance (NMR) 
1H and 13C spectra were recorded on Bruker Avance DRX-500 or DPX-400 MHz spectrometers. The 
HMBC-experiment was performed on a DRX-600 spectrometer. All devices were equipped with direct 
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(600 and 400 MHz) or inverse (500 MHz) dual channel, broadband probe-heads with z-gradients. The NMR 
experiments were performed at 25°C (MeOH calibration). Chemical shifts () are reported in ppm with 
respect tetramethylsilane (TMS). Coupling constants (J) are reported in Hertz (Hz).  
 
4.1.3.2 Mass spectrometry (MS) 
Mass spectra were recorded on an Esquire 3000 plus (Bruker) applying eletron spray ionisation (ESI). High 
resolution mass spectrometry (HRMS) was performed at the University of Fribourg with a Bruker FTMS 
4.7T BioAPEX II device.  
 
4.1.3.3. Elementary Analysis 
Elementary analysis was performed on an Analysator 240 from Perkin-Elmer or a vario MICRO cube from 
Elementar. 
 
4.1.3.4 High Performance Liquid Chromatography (HPLC) 
HPLC measurements were performed on Agilent (or hp) machines equipped with modules from the 1100 
and 1200 series and diode array detectors (UV-detection). HPLC columns were used with the appropriate 
guard columns. Column and conditions are indicated for each compound separately.  
  
4.1.3.5 Gas Chromatography (GC) 
GC measurements were performed on Agilent GCs of the 6890 series equipped with FIDs. Column and 
conditions are indicated for each compound separately.  
 
4.1.3.6 Circular Dichroism (CD) 
CD-spectra were obtained from a Chirascan spectrophotometer from Applied Photophysics Ltd (United 
Kingdom).   
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4.2 Synthesis 
 
4.2.1 Synthesis of [(η5-Cp*)M(biot-p-L)Cl)] (M = Rh, Ir) 
4.2.1.1 N-Boc-N’-(4-Nitrophenylsulfonyl)-ethylenediamine  
 
 
 
A solution of 4-Nitrophenylsulfonyl chloride (7.26 g, 32.8 mmol, 1.05 eq) in 250 ml CH2Cl2 was added 
dropwise to a solution of N-Boc-ethylamine (5 g, 31.2 mmol, 1 eq) and Et3N (8.7 ml, 62.4 mmol, 2 eq) in 
CH2Cl2 (800 ml) at 0 °C. The resulting yellow mixture was stirred over night at RT, was then concentrated 
to 250 ml and washed three times with water (60 ml). The organic phase was dried over Na2SO4 and 
evaporated under reduced pressure to obtain a yellowish solid. The crude product was recrystallised from 
hot ethyl acetate yielding colorless needles (7.74 g, 72% yield). 
1H NMR (400 MHz, MeOH-D4):  1.40 (s, 9H; tBu), 2.99 (m, 2H; ethylenediamine-CH2), 3.09 (m, 2H; 
ethylenediamine-CH2), 8.07 (d, 2H, J = 8.91 Hz; ArH), 8.41 (d, 2H, J = 8.91 Hz; ArH) 
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4.2.1.2 N-Boc-N’-(4-Aminophenylsulfonyl)-ethylenediamine  
 
  
 
An autoclave containing a suspension of Pd/C (5%, 1.1 g) in methanol (60 ml) was charged with N-Boc-
N’-(4-Nitrophenylsulfonyl)-ethylenediamine (7 g, 20.3 mol), purged 3 times with H2 and then filled with 
H2 (15 bars). The mixture was stirred at RT overnight and filtered 3 times through a celite plug. The solvent 
was removed under reduced pressure to obtain the product as a white powder which was used without 
further purification (5.8 g, 96 % yield). 
1H NMR (400 MHz, MeOH-D4):  1.41 (s, 9H; tBu), 2.84 (m, 2H; ethylenediamine-CH2), 3.08 (m, 2H; 
ethylenediamine-CH2), 6.68 (d, 2H, J = 8.7 Hz; ArH), 7.50 (m, 2H, J = 8.7 Hz; ArH). 
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4.2.1.3 N-Boc-N’-(4-Biotinamidophenylsulfonyl)-ethylenediamine 
 
 
 
To a suspension of crude N-Boc-N’-(4-Aminophenylsulfonyl)-ethylenediamine (5 g, 15.8 mmol, 1 eq), 
biotin (3.95 g, 16.2 mmol, 1.02 eq) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (2.95 g, 15.9 mmol, 1.06 eq) 
in acetonitrile (300 ml) was added N-methylmorpholine (2.62 ml, 23.8 mmol, 1.5 eq)  and the mixture was 
stirred for 24 h at RT and then heated to reflux for 3 h. After cooling to RT, water was added (90 ml) and 
the resulting yellowish solution was concentrated under reduced pressure to afford a brownish solid which 
was filtered and washed with CH2Cl2. The crude product was purified by flash chromatography using 
EtOAc/MeOH 8:1 as an eluent.  
 
1H NMR (400 MHz, DMSO-d6):  1.25-1.70 (m, 15H; valeryl-CH2, tBu), 2.36 (m, 2H; valeryl-CH2-CO), 2.59 (d, 1H, 
J = 12.46 Hz; thiophene-CH2), 2.72 (m, 2H; etylenediamine-CH2), 2.83 (dd, 1H, J = 5.09 Hz; thiophene-CH2), 2.94 
(m, 2H; etylenediamine-CH2), 3.12 (m, 1H; thiophene-H), 4.15 (m, 1H; ureido-CH), 4.32 (m, 1H; ureido-CH), 6.37 
(br s, 1H; ureido-NH), 6.45 (br s, 1H; ureido-NH), 6.76 (t, 1H, J = 5.23 Hz; ethylenediamine-NH), 7.51 (t, 1H, J = 
5.75 Hz; ethylenediamine-NH), 7.71 (d, 2H, J = 8.77 Hz; ArH), 7.78 (d, 2H, J = 8.77 Hz; ArH), 10.27 (s, 1H; CO-
NH-Ar). 
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4.2.1.4  N’-(4-Biotinamidophenylsulfonyl)-ethylenediamine TFA salt 
 
 
 
 
 
 
 
To a suspension of N-Boc-N’-(4-Biotinamidophenylsulfonyl)-ethylenediamine (1 g, 1.85 mmol, 1 eq) in 
dry CH2Cl2 (90 ml) was added dropwise trifluoroacetic acid (2.1 ml, 27.8 mmol, 15 eq) at 0°C. The resulting 
yellowish solution was stirred for 6 h at RT and was then evaporated to dryness to obtain a brownish oil. 
The crude product was dissolved in MeOH and ether was added until a white precipitate formed which was 
collected by filtration and dried under reduced pressure (710 mg, 70 % yield).   
1H NMR (400 MHz, DMSO-d6):  1.3-1.75 (m, 6H; valeryl-CH2), 2.37 (m, 2H; valeryl-CH2-CO), 2.58 (d, 1H, J = 
12.51 Hz; thiophene-CH2), 2.8-2.95 (m, 5H; etylenediamine-CH2; thiophene-CH2), 3.13 (m, 1H; thiophene-H), 4.15 
(m, 1H; ureido-CH), 4.31 (m, 1H; ureido-CH), 6.38 (br s, 1H; ureido-NH), 6.45 (br s, 1H; ureido-NH), 7.7-7.9 (m, 
8H; ArH, ethylenediamine-SO2-NH, ethylenediamine-NH3+), 10.34 (s, 1H; CO-NH-Ar) . 
 
ESI-MS (pos. mode): m/z 442.2 ([M+]). 
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4.2.1.5  [(η5-Cp*)Ir(biot-p-L)Cl] 
 
 
 
 
To a mixture of N’-(4-Biotinamidophenylsulfonyl)-ethylenediamine TFA salt (200 mg, 0.36 mmol, 1 eq) 
and [(η5-Cp*)IrCl2]2 (136.4 mg, 0.171 mmol, 0.475 eq) in CH2Cl2 (30 ml) was added Et3N (251 l, 1.8 
mmol, 5 eq) whereupon a color change from orange to dark brown and finally to yellow was observed. 
After stirring for 24 h at room temperature, the resulting yellow precipitate was filtered off, washed with 
CH2Cl2 (3 x 5 ml) and water (3 x 4 ml) and dried in vacuo to obtain the pure product as a bright yellow 
solid (211 mg, 73% yield).   
 
1H NMR (500 MHz, DMSO-d6):  1.25-1.75 (m, 21H; valeryl-CH2, Cp*), 2.25-2.45 (m, 6H; valeryl-CH2-CO, 
ethylenediamine-CH2) , 2.57 (d, 1H, J = 12.51 Hz; thiophene-CH2), 2.82 (dd, 1H, J =  5.15 Hz), 3.12 (m, 1H; 
thiophene-H), 4.14 (m, 1H; ureido-CH), 4.31 (m, 1H; ureido-CH), 5.21 (br s, 2H; ethylenediamine-NH2), 6.37 (br s, 
1H; ureido-NH), 6.44 (br s, 1H; ureido-NH), 7.59 (d, 2H, J = 8.64 Hz; ArH), 7.7 (d, 2H, J = 8.64 Hz; ArH), 10.05(br 
s, 1H; CO-NH-Ar). 
 
13C NMR (400 MHz, DMSO-d6): due to the 
limited solubility of the compound in DMSO the intensity of some signals is to small to be detected) 
 
ESI-MS (pos. mode): m/z 768.22 ([M-Cl]+), 384.18 ([M-Cl]2+), 256.14 ([M-Cl]3+)   
 
Anal. Calcd for C28H41ClIrN5O4S2: C, 41.86 %; H, 5.14 %; N, 8.72 %; found: C, 41.63 %; H, 5.15 %; N, 8.54 %. 
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4.2.1.5 [(η5-Cp*)Rh(biot-p-L)Cl] 
 
 
 
 
[(η5-Cp*)Rh(biot-p-L)Cl] was synthesized applying the same procedure as for [(η5-Cp*)Ir(biot-p-L)Cl] (see 
above) using [(η5-Cp*)RhCl2]2 (53.5 mg, 0.0865 mmol, 0.48 eq),  N’-(4-Biotinamidophenylsulfonyl)-
ethylenediamine TFA salt (100 mg, 0.18 mmol, 1 eq) and NEt3 (125 l, 0.9 mmol, 5 eq) to obtain the 
complex as an orange solid (76 mg, 58 % yield). 
1H NMR (500 MHz, DMSO-d6):  1.25-1.75 (m, 21H; valeryl-CH2, Cp*), 2.2-2.45 (m, 6H; valeryl-CH2-CO, 
ethylenediamine-CH2) , 2.57 (d, 1H, J = 12.02 Hz; thiophene-CH2), 2.82 (dd, 1H, J =  5.07 Hz), 3.12 (m, 1H; 
thiophene-H), 4.13 (m, 1H; ureido-CH), 4.30 (m, 1H; ureido-CH), 6.36 (br s, 1H; ureido-NH), 6.44 (br s, 1H; ureido-
NH), 7.53 (d, 2H, J = 8.07 Hz; ArH), 7.72 (d, 2H, J = 8.63 Hz; ArH), 10.0 (br s, 1H; CO-NH-Ar). 
 
13C NMR (400 MHz, DMSO-d6): due to the limited 
solubility of the compound in DMSO the intensity of some signals is to small to be detected) 
 
ESI-MS (pos. mode): m/z 678.27 ([M-Cl]+)  
 
Anal. Calcd for C28H41ClRhN5O4S2: C, 47.77 %; H, 6.08 %; N, 9.60 %; found: C, 47.93 %; H, 6.21 %; N, 9.87 %. 
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4.2.2 Synthesis of Amino Acid Precursors 
4.2.2.1 Ethyl 4-methyl-2-oxopent-3-enoate1 
 
A solution of dietyloxalate (3 g, 20.5 mmol, 1 eq), dry diethyl ether (20 ml) and dry THF (20 ml) was placed 
in a three necked flask equipped with a mechnical stirrer, a thermometer, a droping funnel and an inlet tube 
for N2 supply. The mixture was cooled to -78 °C and 2-methyl-1-propenyl magnesium bromide (50 ml of 
a 0.5 M solution, 24.5 mmol, 1.2 eq) in THF was added via the dropping funnel within a period of 30 
minutes. After stirring for one hour the reaction was quenched with 2 N H2SO4 (30 ml) and the mixture was 
extracted with diethyl ether (3 x 50 ml). The combined organic fractions were washed with brine (75 ml), 
dried over Na2SO4 and filtered. The solvent was evaporated under reduced pressure to afford a yellowish 
oil which was purified by flash chromatography using cyclohexanes/dichloromethane 1:1 as an eluent. The 
product still contained some diethyloxalate.  
1H NMR (400 MHz, CDCl3):  1.37 (t, 3H, J = 7.3 Hz), 2.03 (d, 3H, J = 1.4 Hz) , 2.24 (d, 3H, J = 0.67 Hz), 4.31 (q, 
2H, J = 7.3 Hz), 6.76 (m, 1H).  
 
13C NMR (400 MHz, CDCl3): 13.97, 21.73, 28.37, 62.11, 119.18, 164.35, 173.15, 197.20. 
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4.2.2.2 4-methyl-2-oxopent-3-enoic acid2 
 
Ethyl 4-methyl-2-oxopent-3-enoate (2 g, 12.8 mmol) was dissloved in ethanol (15 ml) and the solution was 
added to aq. NaOH (0.1 M, 135 ml) in a round-bottomed flask equipped with a mechanical stirrer. After 
stirring for 12 hours, the reaction mixture was acidified with 1 M HCl and extracted with diethyl ether (4 x 
150 ml). The combined organic fractions were dried over Na2SO4 and filtered. The solvent was evaporated 
to yield the crude product as a colorless oil which was purified by flash chromatography using 
EtOAc/AcOH 98:2 as an eluent (0.68 g, 42% yield).  
1H NMR (400 MHz, CDCl3):  2.11 (d, 3H, J = 1.23 Hz), 2.32 (d, 3H, J = 1.06 Hz), 7.05 (m, 1H).  
 
13C NMR (400 MHz, CDCl3): 22.51, 29.07, 116.52, 161.02, 170.15, 181.82. 
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4.2.2.3 Ethyl 3-methyl-2-oxobut-3-enoate1 
 
 
 
A solution of diethyloxalate (3.65 g, 25 mmol, 1eq), dry diethyl ether (25 ml) and dry THF (25 ml) was 
placed in a three necked flask equipped with a mechnical stirrer, a thermometer, a droping funnel and an 
inlet tube for N2 supply. The mixture was cooled to -78 °C and isoprenyl magnesium bromide (60 ml of a 
0.5 M solution, 30 mmol, 1.2 eq) in THF was added via the dropping funnel within a period of 30 minutes. 
The progress of the reaction was monitored by GC. If some diethyloxalate remained in the reaction mixture, 
2 mmol of the Grignard-reagent was added. After completion of the reaction, 2 N H2SO4 (30 ml) was added 
before the mixture was extracted with diethyl ether (3 x 60 ml). The combined organic fractions were 
washed with brine (80 ml), dried over Na2SO4 and filtered. The organic solvent was evaporated under 
reduced pressure to afford a yellowish oil (3.07 g, 86% yield).  
1H NMR (400 MHz, CDCl3): 1.31 (t, 3H, J = 7.0 Hz), 1.87 (m, 3H), 4.23 (q, 2H , J 7.0 Hz), 6.03 (m, 1H), 6.12 (m, 
1H).  
13C NMR (400 MHz, CDCl3): 13.96, 15.82, 61.91, 132.35, 140.43, 164.01, 188.73.  
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4.2.2.4 3-methyl-2-oxobut-3-enoate sodium salt3 
 
Ethyl 3-methyl-2-oxobut-3-enoate (0.43 g, 3 mmol, 1 eq), water (24 ml) and ethanol (2.5 ml) were placed 
in a round-bottomed flask equipped with a mechanical stirrer. 1 M aqueous NaOH (2.7 ml, 2.7 mmol, 0.9 
eq) was added and the mixture was stirred over night. The resulting clear solution was then extracted with 
dichloromethane (12 ml) and diethyl ether (12 ml) and concentrated under reduced pressure. The resulting 
solid was washed with acetone and dried in vacuo to obtain the product as a white solid (0.25 g, 63% yield). 
1H NMR (400 MHz, CDCl3): 1.88 (m, 3H), 6.09 (m, 1H), 6.27 (m, 1H).  
13C NMR (400 MHz, CDCl3): 14.83, 133.22, 140.18, 173.51, 199.53.  
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4.2.3 Synthesis of Reference Compound 
4.2.3.1 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-2,3-dihydroquinolin-4(1H)-one (reduced 
Enrofloxacin)4 
 
 
Enrofloxacin (0.5 g, 1.4 mmol, 1eq) and dry methanol (20 ml) were placed in a round-bottomed flask 
equipped with a mechanical stirrer. To the suspension was added NaBH4 (0.21 g, 5.6 mmol, 4 eq) in portions 
whereupon the reaction mixture immediately turned into a yellow solution. After stirring for 10 minutes, a 
catalytic amount of p-toluenesulfonic acid (small tip of a spatula) was added and the solution was heated 
to 65 °C for 45 minutes. The solvent was evaporated under reduced pressure and the resulting residue was 
dissolved in chloroform. The solution was washed with water, dried over Na2SO4, filtered and evaporated 
under reduced pressure to obtain the product as yellow prisms which were not further purified (0.345 g, 
78% yield).  
1H NMR (400 MHz, CDCl3): 0.72 (m, 2H), 0.9 (m, 2H), 1.13 (t, 3H, J = 7.2 Hz), 2.32 (m, 1H), 2.49 (q, 2H, J = 
7.3 Hz), 2.56-2.65 (m, 6H), 3.27 (t, 4H, J = 4.8 Hz), 3.48, (t, 2H, J = 6.6 Hz), 6.73 (d, 1H, J = 7.6 Hz), 7.52 (d, 1H, J 
= 13.5 Hz). 
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4.3 HABA and CD-Titrations  
 
4.3.1 HABA-titration 
  
Sav-mutants were dissolved in phosphate buffer (20 mM, pH 7) to a tetrameric concentration of 8 M. The 
solution was added to a quartz cuvette (2.4 ml) and treated with 0.3 ml of a 2-(4-hydroxyphenylazo)benzoic 
acid solution (HABA, 9.6 mM in phosphate buffer pH 7). To this mixture was added stepwise 5 L of either 
a biotin solution (0.96 mM in phosphate buffer) or 1.7 l of a [(η5-Cp*)Ir(biot-p-L)Cl] solution (2.9 mM in 
DMF), corresponding to 0.25 equivalents vs. Sav tetramer. The solution was mixed at each step by means 
of pipetting up and down. After 5 minutes, the absorbance at 506 nm was measured.    
 
    
Fig. 4.1. Titration of HABA-saturated Sav-S112A (right) and S112K (left) with biotin (red trace) and [(η5-Cp*)Ir(biot-
p-L)Cl] (green trace). HABA (Ka ≈ 104) is displaced from Sav by a biotinylated probe whereupon the absorption 
maximum max of the dye is shifted from 506 to 350 nm.5 The equivalence point is slightly below 4 due to residual 
biotin or impurities in the protein preparation. As can be appreciated, DMF used as a co-solvent only displaces HABA 
marginally.  
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4.3.2 CD-titration of [(η5-Cp*)Ir(biot-p-L)Cl] towards Sav-S112A and Sav-S112K 
 
Streptavidin mutants were dissolved in MOPS-buffer (0.6 M, pH 7) to a tetrameric concentration of 25 M 
and the resulting solution (2.5 ml) was added to a quartz cuvette (path length: 1 cm). [(η5-Cp*)Ir(biot-p-
L)Cl] was dissolved in DMF to a final concentration of 37.5 mM and 2 l of this solution (corresponds to 
0.5 equivalents [Ir]  vs. Sav-tetramer) was added stepwise to the Sav-solution. The solution was mixed at 
each step by means of pipetting up and down. After 5 minutes, the CD-spectrum was measured in duplicate 
at 25 °C (scan range: 220-500 nm, step resolution: 1 nm, measuring time/wavelength: 1 s). 
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Fig. 4.2. CD-spectra resulting from stepwise addition of [(η5-Cp*)Ir(biot-p-L)Cl] to Sav-S112A (top). A signal arises 
in the near UV region which is absent in the protein (bold line). The CD-signal at selected wavelenghts as a function 
of the [Ir]/Sav ratio (bottom) indicates the acommodation of the metal complex in each biotin binding site of the Sav-
tetramer.    
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Fig. 4.3. CD-spectra resulting from stepwise addition of [(η5-Cp*)Ir(biot-p-L)Cl] to Sav-S112K (top). A signal arises 
in the near UV region which is absent in the protein (bold line). The CD-signal at selected wavelenghts as a function 
of the [Ir]/Sav ratio (bottom) indicates the acommodation of the metal complex in each biotin binding site of the Sav-
tetramer.    
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4.3 NMR experiments to Elucidate the Behavior of 6,7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline in Aqueous Solution 
 
All NMR experiments were performed at 25 °C on a Bruker Avance III NMR spectrometer  operating at 
600.13 MHz, equipped with BBFO smart probe with z-axis pulsed field gradients. Chemical shifts were 
referenced to residual solvent peaks. 
The 1D 1H and 13C spectra were recorded applying water suppression using excitation sculpting with 
gradients. The HMBC spectra were recorded using a standard pulse sequence with presaturation pulses for 
water suppression.  
 
 
4.3.1 HMBC experiment to confirm the ring-closed structure   
The NMR samples contained 80 mM 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline, 160 mM phosphate 
and 5% D2O. The pH was adjusted by addition of either an aqueous NaOH or a HCl solution (0.25 M). 
Measurements were performed at pH 2.5 and 11.5. 
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Fig. 4.3. Two dimensional HMBC spectra of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline in water at pH 2.5 
(top) and 11.5 (bottom). The highlighted cross peaks correspond to a 3J coupling between carbon C1 and hydrogen 
H2, indicating that the compound is present as an imine in both cases. The 5J coupling in the open ketone form would 
result in a much less intensive or absent signal. The chemical shift of C1 further suggests the presence of an imine 
rather than a ketone. 
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4.3.2 1H and 13C NMR measurements to determine the pKa value 
The pKa of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline was determined by measuring the 1H and 13C 
spectra at different pH values in water.  
The NMR samples contained 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline (80 mM), sodium chloride 
(150 mM), 3-(trimethylsilyl)-2,2',3,3'-tetradeuteropropionic acid (2 mM) as an internal standard and 5% 
D2O. For each measurement at a particular pH value a new sample was prepared. The pH was adjusted by 
addition of either an aqueous NaOH or a HCl solution (0.25 M). 
The chemical shifts of selected 1H and 13C nuclei were ploted as a function of the pH and the resulting data 
points were fitted according to the following equation6: 
pH = pK
a - log
δBH+- δobs
δBH+- δB
1 - (
 δBH+- δobs
δBH+- δobs
)
  
where BH+ is the chemical shift of the completely protonated form (in the sample at the lowest pH value), 
BH is the chemical shift of the completely deprotonated form (in the sample of the highest pH value) and 
obs is the observed chemical shift (see table 4.1). 
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pH chemical shift  (ppm) 
 H2 H10 C1 C6 C8 
3.02 3.86 2.76 178.4 158.5 114.9 
5.13 3.86 2.76 178.4 158.5 114.9 
7.09 3.85 2.75 178.2 158.4 114.8 
7.72 3.83 2.72 177.6 158 114.6 
8.18 3.77 2.65 176.5 157.4 114.2 
8.46 3.72 2.58 175.5 156.8 113.5 
8.7 3.66 2.51 174.4 156.2 113.1 
8.91 3.6 2.45 173.3 155.6 112.8 
9.13 3.55 2.38 172.2 155 112.4 
9.4 3.49 2.31 171 154.3 112.1 
9.78 3.43 2.24 170 153.7 111.7 
10.74 3.38 2.18 169 153.2 111.7 
10.87 3.38 2.18 169 153.1 111.7 
11.35 3.37 2.17 168.9 153.1 111.7 
11.64 3.37 2.17 168.9 153.1 111.7 
 
Table 4.1. Chemical shifts of selected 1H and 13C nuclei of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline at 
different pH values. The values are referenced with respect to 3-(trimethylsilyl)-2,2',3,3'-tetradeuteropropionic acid.  
 
                                    
Fig. 4.4. Chemical shifts of selected 1H (left) and 13C (right) nuclei as a function of the pH. The data points were fitted 
as described (solid lines). The corresponding pKa values are: (•) H10: 8.99, (•) H2: 8.91; (•) C8: 8.61, (•) C6: 8.83, (•) 
C1: 8.82.      
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4.4 Catalysis 
 
4.4.1 Control Experiments 
 
 
 
Buffers were prepared by dissolving MOPS (3-morpholinopropane-1-sulfonic acid) and sodium formate in 
water to a final concentration of 0.69 and 3.43 M, respectively. The pH was adjusted to 7 using NaOH. 
[(η5-Cp*)Ir(biot-p-L)Cl] and [(η5-Cp*)Ir(TsEN)Cl] were dissolved in DMF to a final concentration of 10 
mM. The biotinylated ligand (N’-(4-Biotinamidophenylsulfonyl)-ethylenediamine TFA salt) and biotin 
were dissolved in miliQ water to a final concentration of 10 mM. The substrate (6,7-dimethoxy-1-methyl-
3,4-dihydroisoquinoline) was dissolved in miliQ water to a final concentration of 1 M.  
Streptavidin S112A (if present in the reaction) was dissolved in the MOPS/formate buffer to a final 
concentration of 571 M biotin binding sites. According to the experiment (see below), to 175 l of this 
solution was added either the [(η5-Cp*)Ir(biot-p-L)Cl] or the [(η5-Cp*)Ir(TsEN)Cl] stock solution (5 l), 
the ligand stock solution (5 l) and/or the biotin stock solution (10 l). If required, the final volume was 
adjusted by addition of water. The mixtures were stirred for 5 minutes before the reactions were initiated 
by addition of the substrate stock solution (10 l) and stirred. 
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Final volume: 200 l, final concentrations: 0.6 M MOPS, 3 M formate, 500 M Sav biotin binding sites (if 
present), 250 M [(η5-Cp*)Ir(biot-p-L)Cl] or [(η5-Cp*)Ir(TsEN)Cl], 250 M biotinylated ligand (if 
present), 500 M biotin (if present), 50 mM substrate.   
 
Work up and analysis: 
To the reaction mixtures water (500 µl) was added followed by 20% NaOH (50 µl). The mixture was then 
extracted two times with dichloromethane (1 ml),  the combined organic fractions  were collected in a PP 
tube containing  anhydrous sodium sulfate, centrifuged (18800 x g) for 5 minutes and the supernatant was 
analyzed by chiral HPLC using a Chiralpak IC column (5 m, 4.6 mm · 25 mm) and dichloromethane 
containing 1 % isopropanol and 0.06 % diethylamine as an eluent; 1 ml/min; 25 °C, 280 nm, TR 8.5 min 
((S)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline), 9.8 min (6,7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline), 14.6 ((R)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline, referred to as 
salsolidine). Yields were calculated under consideration of a response factor of 1.95. 
 
 
    
Table 4.2. Controll experiments elucidating that the biotinylated Ir-complex is incorporated within Sav during 
catalysis and that the host protein induces the enantioselectivity (TsEN = tosylate ethylenediamine). 
 
 
ID Sav-S112A [( η5-Cp*Ir)(biot-p-L)Cl] [(η5-Cp*)Ir(TsEN)Cl] 
biotinylated 
ligand 
biotin 
conv. 
(%) 
ee  
(%) 
1 yes yes no no no 75 91 (R) 
2 no yes no no no 95 rac 
3 yes no no no no 0 - 
4 yes no yes no no 4 rac 
5 no no yes no no 98 rac 
6 yes no no yes no 0 - 
7 yes yes no no yes 35 14 (R) 
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4.4.2 pH-dependence of [(η5-Cp*)Ir(biot-p-L)Cl]   
 
Buffers were prepared by dissolving MOPS and sodium formate in MiliQ water to a final concentration of 
0.65 and 3.24 M, respectively. The pH was adjusted using conc. H2SO4 or NaOH. [(η5-Cp*)Ir(biot-p-L)Cl] 
was dissolved in DMF to a final concentration of 5 mM. 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 
was dissolved in miliQ water to a final concentration of 1 M.  
Streptavidin mutants (if present in the reaction) were dissolved in the appropriate MOPS/formate buffer to 
a final concentration of 270 M biotin binding sites. To 185 l of this solution was added [(η5-Cp*)Ir(biot-
p-L)Cl] stock solution (5 l) and the mixtures were stirred for 5 minutes. The reactions were initiated by 
addition of the substrate stock solution (10 l). 
Final volume: 200 l, final concentrations: 0.6 M MOPS, 3 M formate, 250 M Sav biotin binding sites, 
125 M [(η5-Cp*)Ir(biot-p-L)Cl], 50 mM substrate.      
The work up of the reactions was performed as described in section 4.4.1. 
   
 
Fig. 4.5. pH profiles of [(η5-Cp*)Ir(biot-p-L)Cl] in the transfer hydrogenation of 6,7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline. Red data points: conversion, blue data points: enantiomeric excess. Left: free complex after 3 
hours, middle: [(η5-Cp*)Ir(biot-p-L)Cl]Sav-S112A after 3 hours, right: [(η5-Cp*)Ir(biot-p-L)Cl]Sav-S112K after 
6 hours. 
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4.4.3 Transfer Hydrogenation of Amino Acid Precursors 
4.4.3.1 4-methyl-2-oxopent-3-enoic acid (quantitative reaction) 
 
4-methyl-2-oxopent-3-enoic acid 1 (25 mg, 0.195 mmol) was dissolved in 4 ml of the reaction buffer 
containing MOPS (0.2 M, pH 7) and sodium formate (0.1 M) and the solution was added to a round 
bottomed flask equipped with a mechanical stirrer. The reaction was initiated by addition of 50 l of a [(η5-
Cp*)Ir(biot-p-L)Cl] stock solution (40 mM in DMF). After stirring over night, the reaction mixture was 
acidified with 1 N H2SO4 and extracted with dichloromethane (4 x 15 ml). The combined organic extracts 
were dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure to obtain colorless 
oil (21.7 mg).  
1H NMR (400 MHz, CDCl3): 1.78 (d, 1.5 H, J = 1.3 Hz), 1.8 (d, 1.5 H, J = 1.1 Hz), 2.1 (d, 3H, J = 1.1 Hz), 1.31 
(d, 3H, J = 1.1 Hz), 4.9 (d, 0.5 H, J = 8.9 Hz), 5.19-5.24 (m, 0.5 H). 
 
 
Fig. 4.6. 1H spectra of the crude reaction mixture resulting from the transfer hydrogenation of 4-methyl-2-oxopent-3-
enoic acid with [(η5-Cp*)Ir(biot-p-L)Cl]. The signals from the product 2b are assigned according to ref. 7. 
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4.4.3.2 3-methyl-2-oxobut-3-enoate (quantitative reaction) 
 
The reaction was performed as described in section 4.4.3.1 with 3-methyl-2-oxobut-3-enoate sodium salt 3 
(25 mg, 0.184 mmol) using either 1 mol% [(η5-Cp*)Ir(biot-p-L)Cl] or [(η5-Cp*)Rh(biot-p-L)Cl].  
 
Reaction with [(η5-Cp*)Ir(biot-p-L)Cl]: 
The corresponding acid of 4a was obtained as a colorless oil (17.7 mg). 
1H NMR (400 MHz, CDCl3): 1.15 (s, 3 H), 1.17 (s, 3 H), 3.31 (m, 1H). 
 
 
Fig. 4.7. 1H spectrum of the crude reaction mixture from the transfer hydrogenation of 3-methyl-2-oxobut-3-enoate 
with [(η5-Cp*)Ir(biot-p-L)Cl]. The small peaks at 4.05 and 0.89 ppm are assigned to product 4c. 
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Reaction with [(η5-Cp*)Rh(biot-p-L)Cl]: 
The corresponding acid of 4a was obtained as a colorless oil (19.1 mg).  
1H NMR (400 MHz, CDCl3): 1.16 (s, 3 H), 1.18 (s, 3 H), 3.33 (m, 1H). 
 
 
Fig. 4.8. 1H spectrum of the crude reaction mixture from the transfer hydrogenation of 3-methyl-2-oxobut-3-enoate 
with [(η5-Cp*)Rh(biot-p-L)Cl].  
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4.4.4 Transfer Hydrogenation of Enrofloxacin 
 
 
The reaction buffer was prepared by dissolving MOPS and sodium formate in water to a final concentration 
of 0.4 and 0.8 M, respectively. The pH was adjusted with NaOH. [(η5-Cp*)M(biot-p-L)Cl] (M = Rh, Ir) 
was dissolved in DMF to a final concentration of 4 mM. Enrofloxacin was dissolved in 12.5 M H2SO4 to a 
final concentration of 10 mM. Sav-mutants (if present in the reaction) were dissolved in the reaction buffer 
to a final concentration of 200 M biotin binding sites. 100 l of this solution was transferred to a PP-tube 
and an appropriate volume of the metal complex stock solution was added. The reaction was initiated by 
addition of 100 ml of the substrate stock solution and the mixtures were shaken at 37°C for 24 hours in an 
incubator (final concentrations: 0.2 M MOPS, 0.4 M formate, 100 M Sav biotin binding sites, 50-250 M 
[(η5-Cp*)M(biot-p-L)Cl], 5 mM Enrofloxacin). 
 
Work up and analysis: 
The reactions were quenched by addition of 50 l of a glutathione solution (250 mM). 50 l of an 
acetophenone solution (35 mM in water) was added as an internal standard followed by 300 l water. 200 
l of this solution was further diluted with 800 l water and analysed by RP-HPLC using an Eclipse XDB-
C18 column (4.6 x 150 mm, particle size: 5 m); solvent A: water containing 0.1% TFA, solvent B: 
acetonitrile; 5% B at 0 min, 30% B at 20 min, 80% B at 22 min, 80% B at 25 min, 5 % B at 5 min, 5% B 
at 5 min; 1 ml/min; 40°C, 254 nm; 14.9 min Enrofloxacin, 16.5 min standard, 17.7 min product. 
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Conversions were determined under consideration of a correlation curve obtained from plotting the ratio of 
the peak areas of the product and the standard as a function of the concentration the product (correlation 
factor: 0.1505, R2 = 0.9997).   
 
 
 
entry SAV-mutant metal complex 
 [M]  
(mM) 
conv. 
 (%) 
1 no Ir 0.05 5 
2 no Ir 0.1 7 
3 no Ir 0.25 9 
4 no Rh 0.05 5 
5 no Rh 0.1 10 
6 no Rh 0.25 19 
7 WT Ir 0.1 6 
8 S112A Ir 0.1 9 
9 S112K Ir 0.1 2 
10 K121A Ir 0.1 10 
11 S112A-K121G Ir 0.1 9 
12 WT Rh 0.1 1 
13 S112A Rh 0.1 5 
14 S112K Rh 0.1 2 
15 K121A Rh 0.1 4 
16 S112A-K121G Rh 0.1 4 
.    
Table 4.3. Initial results obtained in the transfer hydrogenation of Enrofloxacin using [(η5-Cp*)M(biot-p-L)Cl] (M = 
Rh, Ir) and respective ATHases.  
 
 
 
 
 
 
182 Chapter 4: Experimental Part 
4.5 References 
 
1) Rambaud, M.; Bakasse, M,; Duguay, G.; Villieras, J. Synthesis 1988, 7, 564.  
2) Casy, G.; Lee, T.V.; Lovell, H.; Nichols, B.J.; Sessions, R.B.; Holbrook, J.B.  Chem. Soc., Chem. Commun. 1992, 
924. 
3) Casy, G.; Lee, T.V., Lovell, H. Tetrahedron Lett. 1992; 33, 817. 
4) Kondo, H.; Sakamoto, F.; Kawakami, K.; Tsukamoto, G. J. Med. Chem. 1988, 31, 221. 
5) Green, N.M. Methods Enzymol. 1990, 184, 51. 
6) Handloser, C.S.; Chakrabarty, M.R.; Mosher, M.W. Journal of Chemical Education 1973, 50, 511. 
7) Okrasa, K.; Levy, C.; Wilding, M.; Goodall, M.; Baudendistel, N.; Hauer, B.; Leys, D.; Micklefield, J. Angew. 
Chem. Int. Ed. 2009, 48, 7691.
  
 Appendix 
Appendix 
 
List of publications 
 
Dürrenberger, M.; Heinisch, T.; Wilson, Y.M.; Rossel, T.; Nogueira, E.; Knörr, L.; Mutschler, A.; Kersten, K.; 
Malcolm, J.Z.; Pierron, J.; Schirmer, T.; Ward, T.R. Angew. Chem. Int. Ed. 2011, 50, 3026. 
 
Köhler, V.; Wilson, Y. M.; Dürrenberger, M.; Ghislieri, D.; Churakova, E.; Quinto, T.; Knörr, L.; Häussinger, D.; 
Hollmann, F.; Turner, N. J.; Ward, T. R. Nat. Chem. 2013, 5, 93.    
 
Schwizer, F.; Köhler, V.; Dürrenberger, M.; Knörr, L.; Ward, T.R. ACS Catal. 2013, 3, 1752. 
 
Nogueira, E.; Schleier, T.; Dürrenberger, M.; Ballmer-Hofer, K.; Ward, T.R.; Jaussi, R. Prot. Expr. Purif., 2014, 93, 
54. 
 
Dürrenberger, M.; Ward, T.R. Curr. Op. Chem. Bio., 2014, 19, 99. 
 
Wilson, Y.M.; Dürrenberger, M.; Nogueira, E.; Ward, T. R., J. Am. Chem. Soc. 2014, 136, 8928. 
 
Munoz, V.; Dürrenberger, M.; Heinisch, T.; Schirmer, T.; Ward, T.R.; Maréchal, J.D. J. Am. Chem. Soc. 2014, 136, 
15676. 
 
Heinisch, T.; Pellizzoni, M.; Dürrenberger, M.; Tinberg, C.E.; Köhler, V.; Klehr, J.; Häussinger, D.; Baker, D.; 
Ward, T.R. J. Am. Chem. Soc. 2015, 137, 1041
 
  
 
